 
 
 
 
 
 
 
 
PROTOCOL SM04690 -OA-04 
(Amendment 03 Version 00, 23 April 2018)  
 
 
 
 A Phase 2, 24- Week, Multicenter, Randomized, Double-Blind, 
Placebo -Controlled Study Evaluating the Safety and Efficacy of 
SM04690 for the Treatment of Moderately to Severely 
Symptomatic Knee Osteoarthritis  
 
 
NCT 03122860 
 
A Phase 2, 24-Week, Multicenter, Randomized, Double -
Blind, Placebo -Controlled Study Evaluating the Safety and 
Efficacy of SM04690  for the Treatment of  Moderately to 
Severely Symptomatic Knee Osteoarthritis  
 
Study  Number: SM04690 -OA-04 
IND Sponsor: Samumed, LLC  
Version Number:  Amendment 03 Version 00  
Date: 23 April  2018 
 
  Original Protocol Date:  24 January 2017  
Amendment 01 Version 00:  27 March 2017  
Amendment 02 Version 00:  28 June 2017  
SPONSOR SIGNATURE [CONTACT_168998] 2,24-Week ,Multicenter ,Randomized ,Double -Blind ,Placebo -Controlled Study
Evaluating theSafety andEfficacy ofSM04690 fortheTreatment ofModerately toSeverely
Symptomatic Knee Osteoarthritis
Protocol Number :SM04690 -OA-04AM03V00
23April 2018 Date :
Name &Title Signature [CONTACT_1782]
(Qj 9*!>&e(L^Oi2r
L£3
^3/f/yg•><>/#
Samumed commits tosatisfying therequirements oftheICH-GCP Guidelines regarding the
responsibilities oftheSponsor ,theUSCode ofFederal Regulations 21CFR parts 50,54,56,312,and
314,andGood Clinical Practice Guidelines ,asapplicable .
n

Protocol SM04690 -OA-[ADDRESS_197088] OF ABBR EVIATIONS  ................................ ................................ ................................ ...... 5 
STATEMENT OF COMPLIA NCE  ................................ ................................ ............................  8 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...........  9 
SCHEMATIC OF STUDY D ESIGN  ................................ ................................ ........................  16 
1. KEY ROLES  ................................ ................................ ................................ .......................  17 
2. INTRODUCTION: BACKGR OUND INFORMATION & SCIENT IFIC 
RATIONALE  ................................ ................................ ................................ ..............................  17 
2.1 BACKGROUND INFORMATION  ................................ ................................ ........................  17 
2.2 RATIONALE  ................................ ................................ ................................ ....................  18 
2.3 POTENTIAL RISKS AND BENEFITS ................................ ................................ ...................  20 
2.3.1  Known Potential Risks  ................................ ................................ ..............................  20 
2.3.2  Known Potential Benefits  ................................ ................................ .........................  22 
3. OBJECTIVES AND PURPO SE ................................ ................................ ........................  22 
4. STUDY DESIGN AND END POINTS  ................................ ................................ ...............  22 
4.1 DESCRIPTION OF THE STUDY DESIGN  ................................ ................................ .............  22 
4.2 STUDY ENDPOINTS  ................................ ................................ ................................ .........  24 
4.2.1  Primary Endpoints  ................................ ................................ ................................ .... 24 
4.2.2  Secondary Endpoints  ................................ ................................ ................................  24 
4.2.3 Exploratory Endpoints  ................................ ................................ ..............................  24 
5. STUDY ENROLLMENT AND  WITHDRAWAL  ................................ ...........................  25 
5.1 PARTICIPANT INCLUSION CRITERIA  ................................ ................................ ...............  25 
5.2 PARTICIPANT EXCLUSION CRITERIA  ................................ ................................ ..............  25 
5.3 LIFESTYLE GUIDELINES  ................................ ................................ ................................ . 28 
5.3.1  Contraception  ................................ ................................ ................................ ............  28 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ................................ .........................  28 
5.5 PARTICIPANT WITHDRAWAL OR TERMINATION  ................................ .............................  28 
5.5.1  Reasons for Withdrawal or Termination ................................ ................................ ... 28 
5.5.2  Handling of Participant Withdrawals or termination  ................................ ................  29 
5.6 PREMATURE TERMINATION OR SUSPENSION OF STUDY  ................................ .................  29 
6. STUDY AGENT  ................................ ................................ ................................ ..................  29 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  ................................ .............................  [ADDRESS_197089] Storage and Stability ................................ ................................ ....................  30 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   2 6.1.4  Preparation  ................................ ................................ ................................ ................  30 
6.1.5  Dosing and Administration  ................................ ................................ .......................  30 
6.1.6  Route of Administration  ................................ ................................ ...........................  31 
6.1.7  Starting Dose and Dose Escalation Schedule  ................................ ...........................  31 
6.1.8  Dose Adjustments/Modifications/Delays  ................................ ................................ . 31 
6.1.9  Duration of Therapy  ................................ ................................ ................................ .. 31 
6.1.10  Tracking of Dose ................................ ................................ ................................ ....... 31 
6.1.11  Device Specific Considerations  ................................ ................................ ................  31 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ................................ .............................  32 
7. STUDY PROCEDURES AND  SCHEDULE  ................................ ................................ .... 32 
7.1 STUDY PROCEDURES /EVALUATIONS  ................................ ................................ ..............  [ADDRESS_197090] of care study procedures  ................................ ................................ ............  37 
7.2 LABORATORY PROCEDURES /EVALUATIONS  ................................ ................................ ... 37 
7.2.1  Clinical Laboratory Evaluations  ................................ ................................ ...............  37 
7.2.2  Other Assays or Procedures  ................................ ................................ ......................  38 
7.2.3  Specimen Preparation, Handling, and Storage  ................................ .........................  38 
7.2.4  Specimen Shipment  ................................ ................................ ................................ .. 38 
7.3 STUDY SCHEDULE  ................................ ................................ ................................ ..........  38 
7.3.1  Screening ................................ ................................ ................................ ...................  38 
7.3.2  Randomization  ................................ ................................ ................................ ..........  40 
7.3.3  Follow -up ................................ ................................ ................................ ..................  41 
7.3.4  Final Study Visit  ................................ ................................ ................................ ....... 41 
7.3.5  Early Termination Visit  ................................ ................................ ............................  41 
7.3.6  Schedule of Events Table  ................................ ................................ ..........................  42 
7.3.7  Schedule of Electronic Diary and Questionnaire Completion Table  ........................  44 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  ................................ ................................ . 47 
7.5 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ . 47 
7.5.1  Precautionary Medications, Treatments, and Procedures  ................................ .........  47 
7.6 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ...... 47 
7.7 PROPHYLACTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ . 48 
7.8 RESCUE MEDICATIONS , TREATMENTS , AND PROC EDURES  ................................ .............  48 
7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  ................................ ...... 48 
8. ASSESSMENT OF SAFETY  ................................ ................................ .............................  48 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ................................ ................................ ...... 48 
8.1.1  Definition of Adverse Events (AE) ................................ ................................ ...........  48 
8.1.2  Definition of Serious Adverse Events (SAE)  ................................ ...........................  49 
8.1.3  Definition of Unanticipated Problems (UP)  ................................ .............................  [ADDRESS_197091] ................................ ................................ ..........................  52 
8.4.5  Reporting of Pregnancy  ................................ ................................ ............................  52 
8.5 STUDY HALTING RULES  ................................ ................................ ................................ . 52 
8.6 SAFETY OVERSIGHT  ................................ ................................ ................................ ....... 52 
9. CLINICAL MONITORING ................................ ................................ ..............................  52 
10. STATISTICAL CONSIDER ATIONS  ................................ ................................ ..........  53 
10.1  STATISTICAL AND ANALYTICAL PLANS  ................................ ................................ .........  53 
10.2  STATISTICAL HYPOTHESES  ................................ ................................ ............................  53 
10.3  ANALYSIS DATASETS  ................................ ................................ ................................ ..... 53 
10.4  DESCRIPTION OF STATISTICAL METHODS  ................................ ................................ ...... 53 
10.4.1  General Approach  ................................ ................................ ................................ ..... 53 
10.4.2 Analysis of the Primary Endpoint(s) ................................ ................................ .........  53 
10.4.3  Analysis of the Secondary Endpoint(s) ................................ ................................ ..... 54 
10.4.4  Safety Analyses  ................................ ................................ ................................ .........  54 
10.4.5  Baseline Descriptive Statistics  ................................ ................................ ..................  54 
10.4.6  Planned Interim Analyses  ................................ ................................ .........................  54 
10.4.7  Exploratory Analyses  ................................ ................................ ................................  55 
10.4.8  Additional Sub -Group Analyses  ................................ ................................ ...............  55 
10.5  SAMPLE SIZE ................................ ................................ ................................ ..................  56 
10.6  MEASURES TO MINIMIZE BIAS ................................ ................................ .......................  56 
10.6.1  Blinding Procedures  ................................ ................................ ................................ .. 56 
10.6.2  Evaluation of Success of Blinding  ................................ ................................ ............  56 
10.6.3  Breaking the Study Blind/Participant Code  ................................ ..............................  56 
11. SOURCE DOCUMENTS AND  ACCESS TO SOURCE DA TA/DOCUMENTS  .... 57 
12. QUALITY ASSURANCE AN D QUALITY CONTROL  ................................ ............  58 
13. ETHICS/PROTECTION OF  HUMAN SUBJECTS  ................................ ...................  [ADDRESS_197092]  ................................ ................................ ....................  58 
13.3  INFORMED CONSENT PROCESS  ................................ ................................ .......................  58 
13.3.1  Consent/assent and Other Informational Documents Provided to Participants  ........  [ADDRESS_197093] KEEPI[INVESTIGATOR_1645]  ................................ .........................  60 
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  ................................ ...........  60 
14.2  STUDY RECORDS RETENTION  ................................ ................................ ........................  60 
14.3  PROTOCOL DEVIATIONS  ................................ ................................ ................................ . 61 
14.4  PUBLICATION AND DATA SHARING POLICY  ................................ ................................ ... 61 
15. STUDY ADMINISTRATION  ................................ ................................ .......................  61 
15.1  STUDY LEADERSHIP  ................................ ................................ ................................ ....... 61 
16. LITER ATURE REFERENCES  ................................ ................................ ....................  62 
APPENDIX 1.  GUIDANCE FOR INDUSTR Y: TOXICITY SCALE FO R HEALTHY 
ADULT AND ADOLESCENT  VOLUNTEERS ENROLLED  IN PREVENTIVE 
VACCINE TRIALS  ................................ ................................ ................................ ....................  63 
APPENDIX 2.  PROHIBITED CONCOMITA NT MEDICATIONS AND 
PROCEDURES (SUPPLEME NT) ................................ ................................ ............................  [ADDRESS_197094]  Aspartate aminotransferase  
BMI  Body mass index  
CFR  Code of Federal Regulations  
CRF  Case report form  
DLT  Dose -limiting toxicity  
EC Ethics Committee  
eCRF  Electronic case report form  
ECG  Electrocardiogram  
EDC  Electronic data capture  
EOS  End of study  
ePRO  Electronic patient reported outcomes  
ER Emergency room  
ET Early termination  
FAS Full Analysis Set 
FDA  (US) Food and Drug Administration  
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
IA Intra -articular  
IB Investigator Brochure  
Protocol SM04690 -OA-[ADDRESS_197095]  Upper limit of the normal range  
UP Unanticipated problem  
US [LOCATION_002]  
VAS  Visual Analog Scale  
WBC  White blood cell  
WOMAC  Western Ontario and McMaster Universities Arthritis Index  
WPI [INVESTIGATOR_168885]&SS  Widespread Pain Index and Symptom  Severity Form  
 
 
 
 
 
 
 
 
Protocol SM04690 -OA-[ADDRESS_197096] read and understand the protocol and agree to implement the study in accordance with the 
procedures set forth in the protocol and in accordance with the Sponsor's guidelines, all 
applicable government regulations, and the International Conference on Harmonization Good 
Clinical Practice Guidelines E6 (ICH -GCP).  
I will obtain Institutional Review Board/Ethics Committee (IRB/EC) approval of the protocol 
and Informed Consent Form prior to enrollm ent of subjects in the study. I understand that any 
modifications to the protocol made during the course of the study must first be approved by [CONTACT_5040]/EC prior to implementation except when such modification is made to remove an immediate 
hazard to the su bject.  
I will ensure that a fully executed IRB/EC -approved Informed Consent Form is obtained from 
each subject prior to initiation of any study procedures.  
I will allow the Sponsor, Samumed , LLC and its agents, as well as the [LOCATION_002] (US) Food 
and D rug Administration (FDA) and other regulatory agencies, to inspect study facilities and 
pertinent records at reasonable times and in a reasonable manner, ensuring subject 
confidentiality. If I am notified that this study is to be inspected by a regulatory agency, I will 
notify the Sponsor as soon as possible thereafter (no later than 48 hours).  
This protocol contains information that is proprietary to Samumed, LLC. The information 
contained herein is provided for the purpose of conducting a clinical trial f or Samumed , LLC.  
The contents of this protocol may only be disclosed to study personnel under my supervision and 
to my IRB/EC. The contents of this protocol may not be disclosed to any other parties (unless 
such disclosure is required by [CONTACT_168923]) without the prior written approval 
of Samumed , LLC.  
 
__________________________________________  _______________________  
Investigator ’s Signature      [CONTACT_1782]  
 
__________________________________________   
Investigator ’s Printed Name  
 
 
[CONTACT_168999]04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   9 PROTOCOL SUMMARY  
Title:  A Phase 2, 24 -Week, Multicenter, Randomized, Double -Blind, Placebo -
Controlled Study Evaluating the Safety and Efficacy of SM04690 for the 
Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis  
Objectives:  
 Primary:  
The primary objective of this study is to determine  the effectiv e dose(s)  of 
SM04690 for the treatment of knee OA.  
Secondary:  
The secondary objective of this study is to evaluate the safety and 
tolerability of SM04690 . 
Endpoints:  Primary:  
1. Evaluate change from baseline OA pain in the target knee as 
assessed by [CONTACT_168924] (NRS) at Week 24 
2. Evaluate change from baseline OA pain in the target knee as 
assessed by [CONTACT_168925] s 
Osteoarthritis Index (WOMAC) pain subscore at Week 24  
3. Evaluate change from baseline OA function in the target knee as 
assessed by [CONTACT_168926] 24  
4. Evaluate change from baseline in medial joint space width (JSW) 
as documented b y radiograph of the target knee at Week 24  
 
Secondary:  
1. Evaluate the safety of SM04690 as measured by [CONTACT_3148] -
emergent adverse events (TEAEs)  
2. Evaluate change from baseline OA disease activity as assessed by 
[CONTACT_168927] 24 
 
Exploratory :  
1. Evaluate change from baseline OA pain in the target knee as 
assessed by [CONTACT_168928] 4, 8, 12, 16, and 20 
2. Evaluate change from baseline OA function in the target knee as 
assessed by [CONTACT_168926] 4, 8, 12, 
16, and 20   
3. Evaluate change from baseline symptoms of OA in the target knee 
as assessed by [CONTACT_168929] 4, 8, 12, 16, 20, and 
24 
4. Evaluate change from baseline OA pain in the target knee at each 
week  (aside from Week 24)  as assessed by [CONTACT_168930]04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   10 5. Evaluate change from baseline OA disease activity as assessed by 
[CONTACT_168927] 4, 8, 12, 16, and 20 
6. Evaluate change from baseline OA function in the target knee as 
assessed by [CONTACT_168931] 
(KOOS) at Week 4, 8, 12, 16, 20, and 24  
7. Evaluate change from baseline OA function in the target knee at 
each week as assessed by [CONTACT_168932] 
(KOOS -PS) 
8. Evaluate change from baseline OA disease activity as assessed by 
[CONTACT_168933] 4, 12, and [ADDRESS_197097] perception of study treatment received at Week 24  
11. Evaluate outcome differences between treatment with sham or 
placebo injections at Week 4, 8, 12, 16, 20, and 24  
Methodology:  This study will be a multicenter, randomized, double -blind, placebo -
controlled, parallel group study of four different concentrations of 
SM04690 injected into the target knee joint of moderately to severely 
symptomatic osteoarthritis subjects.  
Approximately 630 subjects will be consented  and randomized using a 
perm uted block design  to 6 treatment arms (0.03 mg active per 2 mL 
injection  : 0.07 mg active per 2 mL injection  : 0.15  mg active per 2 mL 
injection  : 0.23 mg active per 2 mL injection  : 0.0 mL vehicle  : 2.0 mL 
vehicle). Subjects will participate in a screenin g period of a minimum of 
10 days and up to 22 days and a 24 -week follow -up period. Clinic visits 
will be scheduled at Screening Visit 1, Screening Visit 2, Day 1, and 
Weeks 4, 12, and 24 [End of study (EOS) ]/Early Termination (ET) . 
Subjects will be require d to complete an electronic diary for the following:  
• Daily pain NRS  (for target knee OA pain)  
• Daily monitoring of usage of NSAIDs  
• Weekly completion of the KOOS -PS 
• Monthly completion of the WOMAC  
• Monthly completion of KOOS  
• Monthly completion of Patient Global Assessment  
Inclusion/  
Exclusion 
Criteria:  Criteria for Inclusion:  
1. Males and females between [ADDRESS_197098] 
American College of Rheumatology (ACR) criteria at Screening 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   11 Visit 1 (clinical AND radiographic criteria) ; OA of the knee is not 
to be secondary to any rheumatologic conditions (e .g., rheumatoid 
arthritis)  
4. Pain compatible with OA of the knee(s) fo r at least 26 weeks prior 
to Screening Visit 1  
5. Primary source of pain throughout the body is  due to OA in the 
target knee  
6. Daily OA knee pain diary average NRS intensity score ≥4 and ≤8 
in the target knee on the 11 -point (0 -10) NRS scale for the [ADDRESS_197099] 4 out of 
the 7 days immediately preceding Day 1   
8. Daily OA knee pain diary average NRS intensity score <4 in the 
non-target knee on the 11 -point (0 -10) NRS scale for the [ADDRESS_197100] 4 out 
of the 7 days immediately precedin g Day 1  
10. Total WOMAC score of 96 -192 (out of 240) for the target knee  at 
baseline  regardless of if the subject is on symptomatic oral 
treatment (baseline questionnaire completed during the screening 
period  prior to randomization ) 
11. Willingness to use an elect ronic diary on a daily basis in the 
evening for the screening period and [ADDRESS_197101]’s Screening Visit  [ADDRESS_197102] occur while enrollment into 
the randomization cohort for which they are eligible is open  
 
Criteria for Exclusion:  
1. Women who are pregnant, lactating, or have a positive pregnancy 
result at Screening Visit [ADDRESS_197103] had surgery to become 
sterilized o r whom are not using a highly effective method of birth 
control    
4. Body mass index (BMI) > 35  
5. Partial or complete joint replacement in either  knee  
6. Currently r equire s: 
a. regular use of ambulatory assistive devices (e.g., 
wheelchair, parallel bars, walker, can es, or crutches) , or 
b. use of a lower extremity prosthesis, and/or a structural knee 
brace  (i.e., a knee brace that contains hardware)   
7. Radiographic disease Stage 0, 1, or 4 in the target knee at 
Screening Visit 1 according to the Kellgren -Lawrence grading o f 
knee OA as assessed by [CONTACT_168934]  
8. Previous participation in a Samumed clinical trial investigating 
SM04690  
9. Any surgery (e.g., arthroscopy) in either  knee within 26 weeks 
prior to Screening Visit 1  
10. Any planned surgery during the study period . Non-surgical 
invasive procedures conducted for a diagnostic or therapeutic 
purpose scheduled during the study period are not prohibited (refer 
to Section 7.6). 
11. Significant and clinically evident misalignment of either  knee that 
would impact subject function, as determined by [CONTACT_737]  
12. History of malignancy within the last 5 years; however, subjects 
with prior history of in situ cancer or basal or squamous cell skin 
cancer are eligible  if completely excised . Subjects with other 
malignancies are eligible if they have been continuously disease 
free for at least [ADDRESS_197104] ion 
13. Clinically significant abnormal screening hematology values, blood 
chemistry values, or urinalysis values as determined by [CONTACT_3786]  
14. Any condition, including laboratory findings (not included in the 
Screening Visit 1 laboratory tests) and findin gs in the medical 
history or in the pre -study assessments, that, in the opi[INVESTIGATOR_684], constitutes a risk or contraindication for participation 
in the study or that could interfere with the study objectives, 
conduct, or evaluation  
15. Comorbid co nditions that could affect study endpoint assessments  
of the target knee, including, but not limited to, rheumatoid 
arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or 
pseudogout , and fibromyalgia  
Protocol SM04690 -OA-[ADDRESS_197105] study endpoint assessments of either  knee, including, but not 
limited to, peripheral neuropathy (e.g., diabetic neuropathy), 
symptomatic hip osteoarthritis, symptomatic degenerative disc 
disease, and patellofemoral syndrome  
17. Any diagnosed psychiatric condition that includes, but is not 
limited to, a history of mania, bipolar disorder, psychotic disorder, 
schizophrenia, schizoaffective disorder, major depressive disorder, 
or generalized anxiety disorder  
18. Participation in a clinic al research trial that included the receipt of 
an investigational product or any experimental therapeutic 
procedure , or an observational research trial related to osteoarthritis  
within 8 weeks prior to any study injection , or planned 
participation in any s uch trial ; the last date of participation in the 
trial, not the last date of receipt of investigational product, must be 
at least 8 weeks prior to Screening Visit  1 
19. Treatment of the target knee with intra -articular glucocorticoids  
(e.g., methylprednisolone) within 12 weeks prior to Screening Visit 
1 
20. Any intra -articular injection into the target knee  with a therapeutic 
aim including , but not limited to , viscosupplementation (e.g., 
hyaluronic acid) , PRP,  and stem cell  therapi[INVESTIGATOR_13553]  24 weeks 
prior to Screening Visit 1 ; treatment of the target knee with intra -
articular glucocorticoids  greater than 12 weeks prior to Screening 
Visit 1 is allowed  
21. Treatment with systemic glucocorticoids  greater than 1 0 mg  
prednisone or the equivalent  per day within 4 weeks prior to 
Screening Visit 1   
22. Effusion of the target knee clinically requiring aspi[INVESTIGATOR_168886] 12 
weeks prior to  Screening Visit  1 
23. Use of electrotherapy, acupuncture, and/or chiropractic treatments 
for knee OA within 4  weeks prior to Screening Visit 1  (refer to 
Appendix 2 ) 
24. Any known active infections, including urinary tract infection, 
upper respi[INVESTIGATOR_1092], sinusitis , suspi[INVESTIGATOR_152434] -
articular infection, hepatitis B or hepatitis C infection, and/or 
infections that may compromise the immune system such as human 
immunodeficiency virus (HIV)  at Day 1  
25. Use of centrally acting analgesics (e.g., duloxetine) (refer to 
Appendix 2 ) within 12 weeks prior to Screening Visit 1  
26. Use of  anticonvulsants not listed in Appendix 2  within 12 weeks 
prior to Screening Visit 1 , unless used for seizure or migraine  
prophylaxis    
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   14 27. Subjects requiring the  usage of opi[INVESTIGATOR_2438]  >1x per week  within 12 
weeks prior to Screening Visit 1  
28. Topi[INVESTIGATOR_168887] (gels, creams, or patches such as the 
Lidoderm patch) used for the treatment of knee OA within 7 days 
of Screening Visit 1  
29. Any chronic condition that has not been well controlled or subjects 
with a chronic condition who hav e not maintained a stable 
therapeutic regimen of a prescription therapy in the opi[INVESTIGATOR_1070]. In addition, subjects with a baseline HbA1c >[ADDRESS_197106] a current or pending disability claim, workers’ 
compensation, or litigation(s) that may c ompromise response to 
treatment  
32. Subjects who are immediate family members (spouse, parent, child, 
or sibling; biological or legally adopted) of personnel directly 
affiliated with the study at any investigative site, or are directly 
affiliated with the stu dy at any investigative site  
33. Subjects employed by [CONTACT_168935], LLC, or any of its affiliates or 
development partners (that is, an employee, temporary contract 
worker, or designee)  responsible for the conduct of the study , or 
who are immediate family members (spouse, parent, child, or 
sibling; biological or legally adopted)  of said employees  
responsible for the conduct of the study  
Population:  Approximately 630 subjects with moderately to severely symptomatic 
osteoarthritis of the knee  
Phase:  2 
Number of Sites 
enrolling 
participants:  This study will be conducted at approximately 80 investigational centers in 
the [LOCATION_002]  
Description of 
Study Agent:  SM04690 is a small molecule inhibitor of the Wnt pathway important in 
driving progenitor cells resident  in the joint to become chondrocytes, 
potentially  enhancing cartilage formation  
Study Duration:  Approximately [ADDRESS_197107] consented: April [ADDRESS_197108] completed: March  2018  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   15 Participant 
Duration:  Up to approximately 27 weeks  
Criteria for 
evaluation:  Efficacy:  
Efficacy will be assessed by:  
• Weekly averages of daily pain NRS  (for target knee OA pain)  
• Monthly WOMAC total score as well as WOMAC pain and 
function subscores for the target knee  
• Weekly KOOS -PS 
• Daily collection of NSAID usage  
• Monthly KOOS  
• Monthly Patient Global Assessment  
• Physician Global Assessment at clinic visits  
• Medial JSW by [CONTACT_168936]:  
The overall safety and tolerability of SM04690 will be determined by 
[CONTACT_5205], seriousness , severity , and relationship  of TEAEs and 
clinically significant changes in clinical laboratory measures and vital 
signs. Changes from baseline in the amount and duration of NSAID 
usage  will be monitored.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol SM04690- OA-04  
Samumed, LLC AM03V00 
23 April 2018 
 
Confidential  16 SCHEMATIC OF STUDY DESIGN 
 
 
 
 
 
 
 
Total N=630
Obtain informed consent .Screen subjects by[CONTACT_168937] ;obtain history ,document .
RadiographScreening
Visit 1
Screening
Visit 2 Electronic diary andquestionnaire training*
Confirm eligibility andrandomize
I I I I I I
0.03 mg
SM04690
n=1050.07 mg
SM04690
n=1050.15 mg
SM04690
n=1050.23 mg
SM04690
n=105Vehicle
n=105Sham
n=105Day1
i i i i i i **
Intra-articular injection
Refer toSection 7.3.6Schedule ofEvents Table
Follow -upassessments ofstudy endpoints andsafety
Refer toSection 7.3.6Schedule ofEvents TableWeek 4
Follow -upassessments ofstudy endpoints andsafety
Refer toSection 7.3.6Schedule ofEvents TableWeek 12
Week 24
(EOS )Radiograph andfinal follow -upassessments ofstudy endpoints andsafety
Refer toSection 7.3.6Schedule ofEvents Table
*Daily pain NRS andNSAIDs electronic diary ,baseline assessments
**Daily pain NRS andNSAIDs electronic diary,weekly KOOS -PS,monthly WOMAC ,KOOS ,
Patient Global Assessment .Refer toSection 7.3.7Schedule ofElectronic Diary and
Questionnaire Completion Table .
Protocol SM04690 -OA-[ADDRESS_197109]   
 
 
 
 
 
Biostatistician   
   
 
 
 
 
 
Data manager   
 
 
 
 
 
Central radiology reader   
 
 
 
Electronic patient reported 
outcomes (ePRO)  eResearchTechnology, Inc. (ERT)  
[ADDRESS_197110].  
Suite 1000  
Philadelphia, PA [ZIP_CODE]   
(215) 972 -0420  
Central laboratory  ACM Global Central Laboratory  
160 Elmgrove Park  
[COMPANY_002]ster, NY [ZIP_CODE]  
([PHONE_3684]  
2. INTRODUCTION : BACKGROUND INFORMA TION & SCIENTIFIC 
RATIONALE  
2.1 BACKGROUND INFORMATI ON  
Osteoarthritis (OA) is the most common form of arthritis and the major cause of activity 
limitation and physical disability in older people. Today, 35 million people (13% of the US 
population) are [ADDRESS_197111] 1 joint. By 2030, 20% of Americans (about 70 million people) will have passed their 65th 

Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   18 birthday and will be at risk for OA (Nevitt et al. 2006 ). 
Therapi[INVESTIGATOR_168888]. Most current treatments are designed only to relieve 
pain and reduce or prevent the disa bility caused by [CONTACT_168938]. Drug 
therapi[INVESTIGATOR_168889]; no treatment inhibits or reverses 
the degenerative structural changes that are responsible for its progression (Nevitt et al. 2006 ). 
Samumed, LLC (Samumed) is developi[INVESTIGATOR_168890]04690 for the treatment of OA. SM04690 is a 
small molecule inhibitor of the Wnt pathway.  
SM04690 has been teste d in a number of appropriate nonclinical studies. The results of those 
studies are included in the Investigator  Brochure (IB).  
2.[ADDRESS_197112] common form of arthritis and chronic joint disorder in man (Dougados 
and Hochberg 2011 ). The exact cause of OA is unknown, but it is associated with aging and 
normal wea r on a joint. O A is characterized by [CONTACT_168939], 
subchondral bone alterations, and synovitis. Patients present with pain and stiffness in the joints, 
with the joints becoming more stiff and immobile over time (Dougados and Hochberg 2011 ). OA 
is a leading cause of physical disability in the US (Lawrence et al. 2008 ).  
The Wnt pathway plays a central role in the initiation and progression of OA pathology and is 
crucial in normal joint metabolism (Hochberg et al. 2012 ). Wnt is a major regulator of joint 
development and is involved in the formation of bone, cartilage, and synovium. The transcri ption 
of Wnt target genes causes an increase in catabolic processes during the development of OA, and 
increased Wnt signaling may contribute to cartilage loss (Gelse et al. 2012 ). Polymorphisms in 
genes involved in Wnt signaling are associated with an increased susceptibility to OA 
development (Wu et al. 2012 ). Established research suggests that modulation of Wnt signaling is 
an attractive tar get for treatment of OA.  
In order to address the need for effective pharmaceutical agents to treat OA, Samumed has used 
structure -based drug design to synthesize a small molecule inhibitor of the Wnt pathway, 
SM04690, as a potential OA therapeutic to be ad ministered in the form of a local injection in the 
affected joint.  
SM04690 was tested in a single phase 1 clinical trial (SM04690 -01) in subjects with moderately 
to severely symptomatic OA of the knee, which was completed on 17Sep2015. The trial was a 
placebo-controlled, double -blind, dose -escalation study of three concentrations of SM04690 
(0.03, 0.07, and 0.23 mg per 2 mL injection), conducted in the US. In each dose cohort, subjects 
were randomized to active or vehicle at a ratio of 16 active: [ADDRESS_197113]. A total of 33/61 (54.1%)  exposed subjects reported no AEs. One SAE 
(paroxysmal tachycardia) reported was deemed unrelated to study medication by [CONTACT_47513] . No clinically significant safety concerns or differences among study groups were 
noted with regard to vital  signs, clinical laboratory results, ECGs , or AEs. Based upon these data, 
a single intra -articular  (IA) injection of SM04690 into the knee of OA subjects appeared safe and 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   19 well-tolerated.  
SM04690 is currently being tested in a phase 2 clinical trial in sub jects with moderately to 
severely symptomatic OA of the knee. The trial is a placebo -controlled, double -blind , parallel 
group study of three concentrations of SM04690 (0.03, 0.07, and 0.23 mg per 2 mL injection)  
injected into the target knee joint , conduct ed in the US . Subjects were randomized at a ratio of 
1:1:1:1 (0.03 mg active per 2 mL injection: 0.07 mg active per 2 mL injection: 0.23 mg active 
per 2 mL injection: placebo). Clinic visits occurred on Treatment Visit Day 1 and Follow -up 
Weeks 4, 13, 26, 39 and 52 [End of study (EOS) ]/Early Termination (ET). As of 30Jun2016, [ADDRESS_197114] withdrawal.   
A phase 3,  long-term extension  study  (SM04690 -OA-05) is also being perfor med to monitor the 
long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously 
injected in the target knee joints of subjects with moderately to severely symptomatic OA from a 
Samumed -sponsored SM04690 -OA phase [ADDRESS_197115] previously been treated with SM04690 or placebo 
injected into the target knee joint. Approximately 2000 subjects will be consented and will 
participate in a 60 month f ollow -up period. Clinic visits are scheduled at Months 6, 12, 24, 36, 
48, and 60  [End of study (EOS)]/Early Termination (ET).  
This phase 2 study, SM04690 -OA-04, is a placebo -controlled, double -blind, parallel group study 
of four concentrations of SM04690 ( 0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected 
into the target knee joint of subjects with moderately to severely symptomatic OA. Based upon 
the interim data analysis of SM04690 -OA-02, key phenotypes of laterality (unilateral vs 
bilateral) as w ell as chronic pain (as measured by [CONTACT_168940]) were identified as 
confounding variables impacting the overall assessment of both radiologic and clinical efficacy 
outcomes. The design of SM04690 -OA-[ADDRESS_197116] of IA saline 
injections on patient -reported outcomes (PRO) such as pain, stiffness, and function in OA 
clinical trials have found statistically and cl inically meaningful improvement in PROs up to 6 
months after injection  (Zhang et al. 2008, Altman et al. 2016, Saltzman et al. 2016 ). Clinically 
noticeable improvements after IA saline injections ultimately call into question the use of such 
injections as a null control group for comparison to investigative trial arms, as saline may 
significantly impac t clinical symptoms . One hypothesis for this mechanism of action is the 
dilution of inflammatory mediators within the knee, providing relief of perceived pain, function, 
as well as stiffness  (Zhang et al. 2008, Altman et al. 2016, Saltzman et al. 2016 ). Determining an 
adequate control to IA saline injection would remain challenging, while it is suggested that a 
sham group with a simple needle stick in to the joint would remedy some concerns for the 
potential therapeutic effect of IA saline injections  (Saltzman et al. 2016 ). 
 
Protocol SM04690 -OA-[ADDRESS_197117] pulse , or s weating .  
SM04690  has been tested in a single phase 1 clinical trial  (SM04690 -01) in humans with 
osteoarthritis (OA) of the knee. In this trial, there was no obvious dose response or difference 
from placebo with respect to the most frequently reported AEs, regardless of whether or not 
considered related to study medication.  A total of 72 AEs were repo rted by 28/61 (45.9%) 
subjects during the study. Sixteen AEs, reported by 8/61 (13.1%) subjects, were considered 
related to study medication by [CONTACT_9673].  The system organ class with the most 
reported AEs was Musculoskeletal and connective  tissue disorders  with 11/61 (18.0%) subjects 
reporting 19 AEs consisting of 5 preferred terms  (arthralgia, back pain, joint swelling, joint 
stiffness, and musculoskeletal chest pain) . Eight of these events  comprising three preferred terms  
(arthralgia, joi nt swelling, and joint stiffness) , reported by 5/61 (8.2%) subjects, were considered 
related to study medication by [CONTACT_9673].  The AE (preferred term) reported most 
was Headache, with 7/61 (11.5%) subjects reporting 7 events of mild or mod erate headache: 2 
reports by 2 (11.8%) subjects in the 0.03 mg treatment group, no reports in the 0.07 mg treatment 
group, 4 reports by 4 (25.0%) subjects in the 0.23 mg treatment group, and 1 report by 1 (9.1%) 
subject in the placebo group. One of these e vents (0.23 mg treatment group) was considered 
related to study medication by [CONTACT_9673]. Headache was the only AE with an 
incidence greater than 10%. The AE (preferred term) with the most events considered related to 
study medication was A rthralgia with 4/61 (6.6%) subjects reporting 4 events which were 
considered treatment related. 3/61 (4.9%) additional subjects reported 5 events of arthralgia 
which were considered unrelated to study medication.  
A single SAE of “tachycardia paroxysmal” oc curred during the study in a subject enrolled in the 
0.07 mg treatment group. The event was a report of tachycardia paroxysmal in a 72 year old 
white male, with previous medical history of tachycardia. This event was considered unrelated to 
study drug admi nistration by [CONTACT_9673]. Nevertheless, as the FDA requested that 
all AEs in this initial study of SM04690 be considered related to study drug, this event was 
reported in an expedited manner to the IND.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   21 Two DLTs were reported on the trial, both occurring in the 0.07 mg treatment group (increased 
knee pain and tachycardia paroxysmal [also an SAE as noted above]). The DLT of increased 
knee pain was considered probably related to treatment by [CONTACT_9673].  
Single intra -articular i njections of SM04690 at doses of 0.[ADDRESS_197118] been  reported in 7/452 (1.5%) 
subjects. The SAEs reported have been Hypertensive crisis, Cholecystitis acute, Gall bladder 
adenocarcinoma, Uterine prolapse, Diverticulitis, Patella fracture, Osteoarthritis (of the hip), and 
Non-cardiac chest pain. These events  were felt to be either not related or unlikely related to study 
medication by [CONTACT_3138].  
Study Placebos  
The 2 possible placebo injections in this study will be either 2 mL of vehicle, which is the 
inactive substance carboxymethylcellulose so dium and polysorbate 80, or a 0 mL sham injection.  
The inactive substance  carboxymethylcellulose sodium and polysorbate 80  is often used as a 
food or drug additive. Potential risks associated with carboxymethylcellulose sodium  and 
polysorbate 80 include al lergic reaction and hypersensitivity.   
The placebo sham injection contains no substance and has the same risks associated with the 
knee joint injection which include bleeding, bruising, infection, pain at the injection site, 
swelling of the knee, and/or i njury to knee joint.  
Risks of Injection  
Risks associated with knee join t injection include bleeding, bruising, infection, p ain at the 
injection site, swelling of the knee, and /or injury to knee joint . 
Risks of Topi[INVESTIGATOR_168891]’  skin are rare and 
may consist of cutaneous lesions (patches of skin that contrast with surrounding skin due to 
differences in texture, thickness, and color), or urticaria (red, raised itchy bumps) . In addition to 
the local reactions, systemic reactions, although much rarer than the local ones, can be seen and 
include edema, bradycardia, dizziness, drowsiness, paresthesia, nausea, vomiting, or 
anaphylactoid reactions (generalized itching and hives, swelli ng, wheezing and difficulty 
breathing, fainting, and/or other allergy symptoms).  
Blood Sampling  
There is some risk of pain or local bruising and infection at the site where blood is drawn for 
laboratory tests. There is also a small risk of a fainting epi[INVESTIGATOR_17110], which can occur as a reaction to 
donating blood.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   22 Knee Radiograph  
This study involves radi ation exposure from a total of 2 radiographs of the subjects’ knees on [ADDRESS_197119]  will receive in this 
study  is expected to be approximately 0.01 mSv and  is less than 1 days’ equivalent dose from 
background radiation. The risk from this dose is small. This radiation exposure may not be 
necessary for the subjects’  medical care , but it is necessary to obtain the research information 
desired.  
2.3.[ADDRESS_197120] s in th is study . 
3. OBJECTIVES AND  PURPOSE  
The purpose of this  study is to evaluate the safety and efficacy of SM04690 injected in the target 
knee joint of moderately to severely symptomatic OA subjects . 
 
Primary  objective : 
The primary objective of this study is to determine  the effective dose(s) of SM04690 for the 
treatment of knee OA.  
Secondary  objective : 
The secondary objective of this study is t o evaluate the safety and tolerability of SM04690 . 
4. STUDY DESIGN AND ENDPOINTS  
4.1 DESCRIPTION OF THE S TUDY DESIGN  
This study is a multicenter, randomized, double -blind, placebo -controlled, parallel group study 
of four different concentrations  of SM04690 injected into the target knee joint of moderately to 
severely symptomatic OA subjects.  
Approximately 630 subjects wi ll be consented  and randomized using a permuted block design  to 
6 treatment arms (0.03 mg active per 2 mL injection  : 0.07 mg active per 2 mL injection  : 0.15  
mg active per 2 mL injection  : 0.23 mg active per 2 mL injection  : 0.0 mL vehicle  : 2.0 mL 
vehicle). To support the primary objective, active treatment groups will be compared to both 
vehicle (2.0 mL vehicle) and sham (0.0 mL vehicle). Subjects will participate in a screening 
period of a minimum of 10 days and up to 22 days and a 24 -week follow -up period. Clinic visits 
will be scheduled at Screening Visit 1, Screening Visit 2, Day 1, and Weeks 4 , 12, and 24 
(EOS )/ET. Specific timing of protocol procedures is described in the Schedule of Events Table  
(Section 7.3.6 ). Specific timing of electronic diary and questionnaire completion is descr ibed in 
the Schedule of Electronic Diary and Questionnaire Completion Table ( Section 7.3.7 ). 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   23 This stu dy will be conducted at approximately 80 investigational centers in the US.  
In this study, subjects will be required to complete an electronic diary for the following:  
• Daily pain NRS  
• Daily monitoring of usage of NSAIDs  
• Weekly completion of the KOOS -PS 
• Monthly completion of the WOMAC  
• Monthly completion of KOOS  
• Monthly completion of Patient Global Assessment  
A Widespread Pain Index and Symptom Severity ( WPI&SS) assessment will be administered at 
Screening Visit 1. Physician Global Assessment will be performed at Day 1 and Weeks 4, 12, 
and 24 (EOS)/ET . Evaluation of the success of blinding will be performed at Day 1 (post intra -
articular injection) and Week 24 (EOS)/ET.    
In addition, general medical evaluations including physical examination , knee examination,  and 
recording of vital signs will be performed at Screening Visit 1, Day 1, and Weeks 4, 12, and 24 
(EOS)/ET . Height will be measured at Screening Visit  1 and weight  will be measured at 
Screening Visit  1 and Week 24 (EOS)/ET . Clinical laboratory evaluations will be performed at 
Screening Visit 1 and Weeks 4, 12, and 24 (EOS)/ET . Radiographic imaging of the knees will be 
performed at Screening Visit 1 and Week 24 (EOS) /ET. 
Recording of signs and symptoms of study medication intolerability and TEAE reporting will 
start following the injection of the study medication and continue until the subject completes 
Week 24 (EOS)/ET . All TEAEs, whether volunteered, elicited, or no ted during examination, will 
be recorded throughout the study . 
Subject Re -Screening  
Subjects are allowed to be re -screened once. Re -screens are limited to subjects who did not meet 
inclusion/exclusion criteria due to a transient reason. Transient refers to self -limiting and 
predictably resolving conditions or acute events (e.g., common co ld, or otitis media), reversible 
medical conditions that are successfully treated (e.g., anemia successfully treated by [CONTACT_104482]), 
and/or being unable to comply with study procedures due to administrative convenience (e.g., 
family issues or attending to a private matter). Diary non -compliance is not a transient event and 
subjects with diary non -compliance may not be re -screened.  
Subjects who failed any entry criteria for which no further treatment or spontaneous resolution is 
expected are not allowed to be re-screened.  
Any re -screened subject must be re -consented and will be issued a new subject number. All 
screening procedures and assessments , except for the knee radiograph  (if taken at previous 
screen) , must be performed a t re-screen; no results or data, except for the knee radiograph, may 
be used from the previous screen.  Target knee selection may not be changed at re -screen.  
 
 
 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   24 4.2 STUDY ENDPOINTS  
4.2.1  PRIMARY ENDPOINT S 
1. Evaluate change from baseline OA pain in the target knee as assessed by [CONTACT_168941] (NRS) at Week 24  
2. Evaluate change from baseline OA pain in the target knee as assessed by [CONTACT_168942] (WOMAC) pain subscore at Week 24  
3. Evaluate change from baseline OA function in the target knee as assessed by [CONTACT_168943] 24  
4. Evaluate change from baseline in medial joint space width (JSW) as documented by 
[CONTACT_168944] 2 4  
4.2.2  SECONDARY ENDPOI NTS  
1. Evaluate the safety of SM04690 as measured by [CONTACT_3148] -emergent adverse events 
(TEAEs)  
2. Evaluate change from baseline OA disease activity as assessed by [CONTACT_168945] 24 
4.2.3  EXPLORATORY ENDPOINT S 
1. Evaluate change from baseline OA pain in  the target knee as assessed by [CONTACT_168946] 4, 8, 12, 16, and 20  
2. Evaluate change from baseline OA function in the target knee as assessed by [CONTACT_168943] 4, 8, 12, 16 , and 20  
3. Evaluate change from baseline sympto ms of OA in the target knee as assessed by 
[CONTACT_168929] 4, 8, 12, 16, 20, and 24  
4. Evaluate change from baseline OA pain in the target knee at each week (aside from Week 
24) as assessed by [CONTACT_168947]  
5. Evaluate change from baseline OA disease activity as assessed by [CONTACT_168945] 4, 8, 12, 16, and 20 
6. Evaluate change from baseline OA function in the target knee as assessed by [CONTACT_168948] (KOOS) at Week 4, 8, 12, 16, 20, and  24 
7. Evaluate change from baseline OA function in the target knee at each week as assessed 
by [CONTACT_168932] (KOOS -PS) 
8. Evaluate change from baseline OA disease activity as assessed by [CONTACT_168949] 4, 12, and [ADDRESS_197121] fulfill all of the following criteria:  
1. Males and females between [ADDRESS_197122] American College of 
Rheumatology (ACR) criteria at Screening Visit 1 (clinical AND radiographic criteria) ; 
OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid 
arthritis)  
4. Pain compatible with OA of the knee(s) for at least 26 weeks prior to Screening Visit 1  
5. Primary source of pain throughout the body is  due to OA in the target knee  
6. Daily OA knee pain diary average NRS intensity score ≥4 and ≤8 in the target knee on 
the 11 -point (0 -10) NRS scale for the [ADDRESS_197123] 4 out of the 7 days immediately 
preceding Day 1  
8. Daily OA knee pain diary average NRS intensity score <4 in the non -target knee on the 
11-point (0 -10) NRS scale for the [ADDRESS_197124] 4 out of the 7 days 
immediately preceding Day 1  
10. Total WOMAC score of 96 -192 (out of 240) for the target knee  at ba seline  regardless of 
if the subject is on symptomatic oral treatment (baseline questionnaire completed during 
the screening period  prior to randomization ) 
11. Willingness to use an electronic diary on a daily basis in the evening for the screening 
period and [ADDRESS_197125]’s Screening Visit  [ADDRESS_197126] who meets one or mor e of the following criteria will not be included in this 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   26 study:  
1. Women who are pregnant, lactating, or have a positive pregnancy result at Screening 
Visit [ADDRESS_197127] had surgery to become sterilized or whom are not using a highly 
effective method of birth control    
4. Body mass index (BMI) > 35  
5. Partial or complete joint replacement in either  knee  
6. Currently r equire s: 
a. regular use of ambulatory assistive devices (e.g., wheelchair, parallel bars, walker, 
canes, or crutches), or  
b. use of a lower extremity prosthesis, and/or a structural knee brace  (i.e., a knee 
brace that contains hardware)  
7. Radiographic disease Stage 0, 1, or 4 in the target knee at Screening Visit 1  according to 
the Kellgren -Lawrence grading of knee OA as assessed by [CONTACT_168934]  
8. Previous participation in a Samumed clinical trial investigating SM04690  
9. Any surgery (e.g., arthroscopy) in either  knee within 26 weeks prior to Screening Vis it 1 
10. Any planned surgery during the study period. Non-surgical invasive procedures 
conducted for a diagnostic or therapeutic purpose scheduled during the study period are 
not prohibited (refer to Section 7.6). 
11. Significant and clinically evident misalignment of either  knee that would impact subject 
function, as determined by [CONTACT_737]  
12. History of malignancy within the last 5 years; however, subjects with prior history of in 
situ cancer or basal or squamous cell skin cancer are eligible  if completely excised . 
Subjects with other malignancies are eligible if they have been continuously disease free 
for at least [ADDRESS_197128] ion 
13. Clinically significant abnormal screening hematology values, blood chemistry values, or 
urinalysis values as determined by [CONTACT_737]  
14. Any condition, including laboratory findings (not included in the Screening Visit 1 
laboratory tests) and findin gs in the medical history or in the pre -study assessments, that, 
in the opi[INVESTIGATOR_689], constitutes a risk or contraindication for participation in 
the study or that could interfere with the study objectives, conduct, or evaluation  
15. Comorbid co nditions that could affect study endpoint assessments  of the target knee, 
including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus 
erythematosus, gout or pseudogout , and fibromyalgia  
16. Other conditions that, in the opi[INVESTIGATOR_689], could affect study endpoint 
assessments of either  knee, including, but not limited to, peripheral neuropathy (e.g., 
diabetic neuropathy), symptomatic hip osteoarthritis, symptomatic degenerative disc 
disease, and patellofemoral syndrome  
Protocol SM04690 -OA-[ADDRESS_197129] or any experimental therapeutic procedure , or an observational research trial 
related to osteoarthritis  within 8 weeks prior to any study injection , or planned 
participation in any s uch trial ; the last date of participation in the trial, not the last date of 
receipt of investigational product, must be at least 8 weeks prior to Screening Visit  1 
19. Treatment of the target knee with intra -articular glucocorticoids  (e.g., 
methylprednisolone ) within 12 weeks prior to Screening Visit 1  
20. Any intra -articular injection into the target knee with a therapeutic aim including , but not 
limited to , viscosupplementation (e.g., hyaluronic acid) , PRP, and stem cell therapi[INVESTIGATOR_168892] 24 weeks prior to Screening Visit 1 ; treatment of the target knee with intra -
articular glucocorticoids  greater than 12 weeks prior to Screening Visit 1 is allowed  
21. Treatment with systemic glucocorticoids  greater than 1 0 mg  prednisone or the equivalent  
per day within 4 weeks prior to Screening Visit 1   
22. Effusion of the target knee clinically requiring aspi[INVESTIGATOR_168886] 12 weeks prior to  
Screening Visit  1 
23. Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 
4 weeks prior to Screening Visit 1 (ref er to Appendix 2 ) 
24. Any known active infections, including urinary tract infection, upper respi[INVESTIGATOR_4348], sinusitis, suspi[INVESTIGATOR_152434] -articular infection, hepatitis B or hepatitis C 
infection, an d/or infections that may compromise the immune system such as human 
immunodeficiency virus (HIV)  at Day 1  
25. Use of centrally acting analgesics (e.g., duloxetine) (refer to Appendix 2 ) within 12 
weeks prior to Screening Visit 1  
26. Use of anticonvulsants not listed in Appendix 2  within 12 weeks prior  to Screening Visit 
1, unless used for seizure or migraine prophylaxis    
27. Subjects requiring the us age of opi[INVESTIGATOR_2438] >1x per week within 12 weeks prior to Screening 
Visit 1  
28. Topi[INVESTIGATOR_168887] (gels, creams, or patches such as the Lidoderm patch) 
used for the treatment of knee OA within 7 days of Screening Visit 1  
29. Any chronic condition that has not been well controlled or subjects with a chronic 
condition who hav e not maintained a stable therapeutic regimen of a prescription therapy 
in the opi[INVESTIGATOR_871]. In addition, subjects with a baseline HbA1c >[ADDRESS_197130] a current or pending disability claim, workers’ compensation, or 
litigation(s) that may compromise response to treatment  
32. Subjects who are immediate family members (spouse,  parent, child, or sibling; biological 
or legally adopted) of personnel directly affiliated with the study at any investigative site, 
or are directly affiliated with the study at any investigative site  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   28 33. Subjects employed by [CONTACT_168935], LLC, or any of its affi liates or development partners 
(that is, an employee, temporary contract worker, or designee)  responsible for the 
conduct of the study , or who are immediate family members (spouse, parent, child, or 
sibling; biological or legally adopted)  of said employees  responsible for the conduct of 
the study  
5.3 LIFESTYLE GUIDELINES  
5.3.1  CONTRACEPTION  
From Screening Visit 1  until Week 24  (EOS)/ET , all subjects must agree to be strictly abstinent 
from sexual intercourse  or use an acceptable form of contraception as defined by t his protocol  if 
the subject or their partner is capable of becoming pregnant.  
Sexually active subjects must use one of the following methods of contraception from Screening 
Visit 1 until Week 24 (EOS)/ET : 
1. Use of a condom for males with a vasectomy (vasectomy must have been performed at 
least 6 months prior to Screening Visit  1) 
2. Males without a vasectomy or a vasectomy performed within [ADDRESS_197131] use a condom and be instructed that their female partner (s), if any,  must be 
of nonchildbearing potential or use another form of highly effective birth control which 
includes the following:  
a. Double barrier methods of contraception such as condom plus diaphragm or 
cervical/vault cap with spermicide  (i.e., physical plus chemi cal) 
b. Established hormonal contraceptive methods. Females who are using hormonal 
contraceptives must have had consistent use of the same hormonal contraceptive 
product for at least [ADDRESS_197132] continue to use the same 
contraceptive duri ng the study  
c. Intrauterine device (IUD)  
d. Surgically sterile (e.g., bilateral tubal ligation/occlusion, hysterectomy)  
e. Postmenopausal  
3. Women  of childbearing potential must agree to use a highly effective method of 
contraception  (as described in #2 above)  and be instructed that their male partner (s), if 
any, must use  a condom  
5.[ADDRESS_197133] who signed informed consent ceases participation in this study, regardless 
of circumstances, prior to completion of the defined study period.  Subjects can be prematurely 
discontinued from the study fo r one of the following reasons:  
• Death  
• Lost to follow -up after a minimum of [ADDRESS_197134], including sending a registered letter  
• Subject withdraws consent  
• TEAE  
• Subject non -compliance  
• Request by [CONTACT_168950]  
• Study terminated by [CONTACT_168951] a subject from the study if, in the Investigator 's opi[INVESTIGATOR_1649], it is not in 
the best interest of the subject to continue in the study . 
5.5.2  HANDLING OF PARTICIPANT  WITHDRAWALS OR TERMINATION  
In case of premature discontinuation of study participation, Week 24 (EOS)/ET  procedures 
should be conducted within [ADDRESS_197135]/Ethics Committee (IRB/EC) reserve the 
right to prematurely terminate the study in the interest of subject safety and welfare. The Sp onsor 
reserves the right to prematurely terminate the study at any time for administrative or safety 
reasons.  Written notification, documenting the reason for study suspension or termination, will 
be provided by [CONTACT_168952] I nvestigator, Sponsor, and regulatory 
authorities as appropriate. If the study is prematurely terminated or suspended, the Investigator 
will promptly inform the IRB and will provide the reason(s) for the termination or suspension.  
6. STUDY AGENT  
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  
6.1.[ADDRESS_197136] is a sterile suspension 
in diluent containing 0.5% carboxymethylcellulose sodium and 0.05% polysorbate [ADDRESS_197137] contains  0.5% carboxymethylcellulose 
sodium and 0.05% polysorbate 80 in p H 7.4 phosphate buffered saline . The placebo will be 
vehicle only or a sham injection.  
SM04690 and vehicle are manufactured by [CONTACT_168953], Inc. (San Diego, CA) and will be 
supplied as single -use injections. SM04690  and vehicle will be supplied to the study pharmacist 
and labeled according to the applicable local and country regulations. For dispensing , dose 
preparation , and labeling instructions, refer to the Pharmacy Manual.  
6.1.[ADDRESS_197138] be stored at the appropriate temperature  (15°-30°C or 
59°-86°F) and in a restricted area with limited access . Temperature excursions are allowed 
between 2° -60°C (36° -140°F)  for a time period not to exceed  a cumulative of  [ADDRESS_197139] and adding to a 
vehicle (diluent) vial, mixing well to re -suspend the product, then injecting 2 mL intra -articularly  
into the target knee . Refer to the Pharmacy Manual for detai led instructions on study medication 
preparation .  
6.1.5  DOSING AND ADMINISTR ATION  
SM04690 will be administered in the following dosage strengths:  
• SM04690 0.0 3 mg in 2  mL Injectable Suspension  
• SM04690 0. 07 mg in 2  mL Injectable Suspension  
• SM04690 0.15 mg in 2 mL Injectable Suspension  
• SM04690 0. 23 mg in 2  mL Injectable Suspension  
• SM04690 0 mg; 2 mL vehicle  injection only  
• SM04690 0 mg; 0 mL sham injection  (intra -articular injection procedure is performed 
identically to all other treatment gr oups  but without the injection of any liquid)  
Each subject will be consented and randomized using a permuted block design  to [ADDRESS_197140] igator.  
Only topi[INVESTIGATOR_15413] (absolutely no invasive anesthetic) is allowed for the study injections. 
Protocol SM04690 -OA-[ADDRESS_197141] should be blinded to 
observation of the study medication and injection procedure according to the processes specified 
in the Site-Specific  Blinding Plan.  
The unblinded Investigator (injector) should place the needle into the joint  and, while n ot 
required, if it is the standard practice of the Investigator, a small amount (0.3 -0.5 mL) of joint 
fluid can be aspi[INVESTIGATOR_3831] (if present) in order to confirm correct needle placement ; the aspi[INVESTIGATOR_168893] -injected . Thereafter, the tot al volume contained in the syringe is to 
be injected into the joint space of subjects that were randomized to either active or vehicle arms. 
In subjects randomized to sham injection (only intra -articular positioning of the needle without 
volume application ), while not required, if it is the standard practice of the Investigator, a small 
amount (0.3 -0.5 mL) of joint fluid can be aspi[INVESTIGATOR_3831] (if present) in order to confirm correct needle 
placement . The duration that the needle remains inside the joint as well as the pressure that is 
applied should be similar to the active and vehicle injections in order to minimize subject 
awareness that they are receivi ng a sham injection. Unblinded I nvestigator s (injector s) 
participating in the trial should  also inform subjec ts that they may or may not feel any sensation 
related to the injection.  
6.1.[ADDRESS_197142] will be randomly assigned to a dose on Day 1.  
6.1.8  DOSE ADJUSTMENTS/MOD IFICATIONS/DELAYS  
No modification in the specified dose concentration or the volume (2 mL , or 0 mL for sham ) of 
the study medication  or vehicle  injected into the target knee joint will be allowed . 
6.1.[ADDRESS_197143] also be logged. The log includes the following:  
• Subject number and initials  
• Date that study medication was prepared/injected  
• Quantity dispensed  (active vial, veh icle vial)  
• Quantity returned /used  (active vial, vehicle vial)  
All study medication and vehicle prepared  and dispensed by [CONTACT_168954]/or 
unblinded designee  will be inventoried and accounted for throughout the study.  The unblinded  
Investig ator and/or unblinded designee  must maintain an accurate, up -to-date dispensing log for 
all study medications supplied by [CONTACT_1034] . Study medication and vehicle dispensed for all 
subjects must be recorded on the drug accountability form s. The study medi cation dispensing log 
and remaining drug inventory will be reviewed by [CONTACT_1034] -designated  unblinded  clinical 
monitor.  
The study medication s supplied for this study are for use only in subjects properly consented and 
randomized  into this protocol.  Used and unused s tudy medications must be kept in a secure , 
blinded  location physically separated from standard clinic or office drug supplies , and with 
access limited to the unblinded Investigator and/or unblinded designee . Procedures for 
Investigator return or destruction of used and unused vials  of the study medication and vehicle  
will be provided in the Pharmacy Manual.   
7. STUDY PROCEDURES AND  SCHEDULE  
7.1 STUDY PROCEDURES/EVA LUATIONS  
7.1.1  STUDY SPECIFIC PROCE DURES  
Collection of Adverse Events Data  
Data regarding  treatment -emergent adverse events (TEAEs)  will be collected in this study.  
TEAEs are events that occur during the course of the study that are not present prior to Day [ADDRESS_197144] 
worsened in severity during the course of the study.  TEAEs  will be assessed at each study visit 
from the time of study medication injection on study visit Day 1  through Week 24 (EOS)/ET .  
Each subject will be observed and queried by [CONTACT_168955] ’s designee at 
each study visit for any continuing TEAEs or new TEAEs since the previous visit.  The subject 
may be asked to return to the site  for an unscheduled visit if a TE AE occurs between study visits,  
and if, in the opi[INVESTIGATOR_689] , the TEAE requires a study visit for full evaluation.  Any 
TEAE reported by [CONTACT_168956] ’s designee will be 
recorded within the  eCRF . The following information will be recorded for each TEAE : 
description of the event, date of onset and resolution, etiology, and severity as assessed by [CONTACT_168957] “Guidance for Industry:  Toxicity Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Trials”  (Appendix 1 ), causal relationship 
Protocol SM04690 -OA-[ADDRESS_197145]’s last visit will be followed until the 
study close -out visit, if requested . Serious adverse events that are not resolved or stabilized 
during this time period will be followed until resolution or stabil ization . 
Medical History  
A medic al history will be obtained at S creening  Visit 1 and Day 1 with a follow -up at Week 24 
(EOS)/ET . Medical history  at Screeni ng Visit 1  will include demographic data (e.g., age, race , 
ethnicity)  and usage of assistive devices . In addition, medical information will also be recorded, 
including all (1)  medical conditions and disease states that require current or ongoing therapy 
and (2)  other medical conditions and disease states that, in the opi[INVESTIGATOR_689] , are 
relev ant to the subject’s study participation.  Review of medical history at the Week 24 (EOS)/ET  
visit will only be to capture End Dates of any ongoing medical history collected at screening . 
Physical Examination  
A general physical ex amination will be conducted at Screening  Visit 1,  Day 1, and Weeks 4, 12, 
and 24 (EOS)/ET . Results of the physical examination will be  noted in the source documents. 
Any clinically significant finding noted prior to study medication injection should  be rec orded as 
medical history. If it is found after study medication injecti on, it should be reported as a TE AE.  
Knee Examination  
A knee examination of both knees will be conducted at Screening  Visit 1, Day 1, and Weeks 4, 
12, and 24 (EOS)/ET . Results of the k nee examination will be noted in the source documents.  
Any clinically significant finding noted prior to study medication injection should  be recorded as 
medical history. If it is found after study medication injecti on, it should be reported as a TE AE.  
Presence of bilateral knee OA (yes/no) will be recorded in the eCRF  at Screening Visit [ADDRESS_197146]’s evaluation and  the Investigator’s clinical judgment . 
Misalignment of both knees  will be assessed by [CONTACT_168958]  1. In the opi[INVESTIGATOR_689], subjects with s ignificant and clinically 
evident misalignment in either knee that would impact subject function  must be excluded from 
the study.  
Vital Signs  
Vital signs will be measured by a qualified staff member  at Screening  Visit 1, Day 1, and Weeks 
4, 12, and 24 (EOS)/ET . 
At each time point, the following vital signs will be measured:  
• Body temperature  
• Pulse rate  
• Respi[INVESTIGATOR_1487]  
• Blood pressure (systolic and diastolic) after the subject rests ( sitting or supi[INVESTIGATOR_050])  for at 
least 5  minutes ; same resting position should be used for all blood pressure 
Protocol SM04690 -OA-[ADDRESS_197147] be recorded as medical history if found prior to stud y medication injection or as a TE AE if 
found after study medication injection .  
Height and Weight  
Height measurements will be taken at  Screening Visit  1 only.  Weight  measurements will be 
taken at S creening Visit  1 and Week 24  (EOS)/E T. 
Radiograph  of Knee Joints  
Radiograph  of the knee joint s will be taken at Screening Visit 1  and Week 24  (EOS)/ ET.  
Detailed instructions for obtaining and managing the radiographs  will be provided to the 
investigational center prior to the initiation of subject enrollment.  The intent ( as described  in the 
Image Review Charter – Image Acquisition Guidelines) is that radiographs  should be obtained in 
the poster ior-anterior (PA) view, whenever possible.   
All radiographs will be submitted to an independent radiologist who will document disease stage 
according to the Kellgren -Lawrence grading scale for compliance with inclusion/exclusion 
criteria, as well as JSW  for efficacy assessments . 
Widespread Pain Index and Symptom Severity (WPI &SS) Form  
The WPI &SS assessment consists of a body map that determines a subject’s areas of pain or 
tenderness  [Widespread Pain Index (WPI)] and symptom severity  (SS) questions  (Clauw 2014) . 
A WPI &SS assessment will be completed by [CONTACT_168959] 1 on paper .  
Upon completion of the WPI&SS assessment, the subject will sign/initial and date the source 
document to indicate that the assessments are reported accurately.  
The WPI&SS assessment sheets will be provided by [CONTACT_168960].  
Electroni c Diary Device Provision and Training  
Electronic diary device provis ion will occur at Screening Visit 2. S ubjects will be trained on 
electronic diary and questionnaire completion  at Screening Visit 2.  Subject training will include 
details on what medicatio ns are NSAID s. Detailed instructions for subject training and electronic 
questionnaire completion will be provided to the investigational center. Electronic devices are to 
be returned to the site at Week 24 (EOS)/ET.  
Electronic devices will store completed  questionnaire data for up to [ADDRESS_197148] ePRO data and compliance reports in the 
ePRO vendor web portal (StudyWorks ) at least once a week or more frequently as needed  to 
ensure timely subject completion and transmission of questionnaire data between study visits . 
Pain Numeric Rating  Scale ( NRS ) 
The pain NRS is an 11 -point scale (0 -10) for subject self -reporting of average knee pain  in the 
last [ADDRESS_197149] ability to be compliant with 
a daily pain assessment . During the screening period, daily pain NRS assessments will be 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   35 complete d by [CONTACT_168961]  (between 5:00  pm and 11: 59 pm) remotely on their 
electronic devices  for each knee  to collect average knee pain in the last [ADDRESS_197150] 
electronic diary compliance for daily pain NRS over the screening period will be reviewed at 
Day 1 prior to randomization . After s creening , starting on Day 1, daily  pain NRS assessments are 
to be completed by [CONTACT_168961] (between 5:00 pm and 11:59 pm)  remotely on their 
electronic devices  for the target knee only . Refer to Section 7.3.[ADDRESS_197151], regardless of  pain 
NRS scores.  
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Electronic Diary  
The daily  electronic diary of NSAID usage will document subject usage of any NSAID 
medication as “yes” or “no” in response t o the following question, “Did you take any medic ation 
that is an NSAID in the last 24 hours?”.  Starting on the day of Screening Visit 2 after the site 
visit, daily  electronic diary of NSAID usage is to be  completed by [CONTACT_168962] 
(between 5:00 pm and 11:59 pm)  remotely on their electronic d evices . Refer to Section 7.3.[ADDRESS_197152].  
Western Ontario and McMaster Universities Arthritis Index (WOMAC)  
The WOMAC is a widely -used, proprietary outcome measur ement tool used by [CONTACT_168963], including pain, 
stiffness, and physical functioning of a target joint . The WOMAC Version NR S 3.[ADDRESS_197153]  for their target knee  in the evening (between 5:00 
pm and 11:59 pm) remotely on their electronic devices on Screening  Visit 2 + 5 days ( or up until 
the day before the Day 1 visit ). WOMAC questionnaire completion  will be reviewed at Day [ADDRESS_197154] eligibility. After Day 1 , monthly  (every 4 weeks)  
WOMAC assessments will be completed by [CONTACT_168964]  
(between 5:00  pm and 11:59  pm) remotely on their electronic devices . Refer to Section 7.3.7  for 
a schedule of electronic diary and questionnaire completion.  
Subjects will complete the WOMAC on the Sponsor -provided electronic device.  Subjects will 
receive notifications reminding them to complete the monthly WOMAC assessment.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   36 Knee Injury and Osteoarthritis Outcome Score (KOOS)  
KOOS is a widely -used, non -proprietary tool used by [CONTACT_168965] a subject’s 
opi[INVESTIGATOR_168894]. KOOS evaluates pain, symptoms, [ADDRESS_197155] for their target knee in the evening (between 5:00 pm and 11:59 pm)  remotely on 
their electronic devices  on Screening  Visit 2 + 5 days ( or up until the day before the Day 1 visit ). 
After Day 1, monthly  (every 4 weeks)  KOOS questionnaires  will be completed by [CONTACT_168966]  (between 5:00 pm and 11:59 pm)  remot ely on their electronic devices . Refer to 
Section 7.3.7  for a schedule of electronic diary and questionnaire completion.  
Subjects will complete the  KOOS questionnaire on the Sponsor -provided electronic device. 
Subjects will receive notifications reminding them to complete the monthly KOOS assessment.  
KOOS Physical Function Short Form (KOOS -PS) 
KOOS -PS is derived from the KOOS and is used to assess a subject’s opi[INVESTIGATOR_168895]. The KOOS -PS 
questionnaire will be completed by [CONTACT_168967]  (between 5:00 
pm and 11:59 pm)  remotely on their electronic devices  on Screening  Visit 2 + 5 days ( or up until 
the day before the Day 1 visit ). After Day 1, weekly (every 7 days) KOOS -PS questionnaires 
will be completed by [CONTACT_168968]  (between 5:00 pm and 11:59 pm)  remotely on 
their electronic devices . Refer to Section 7.3.7  for a schedule of electronic diary and 
questionnaire comple tion. 
Subjects will complete the KOOS -PS questionnaire on the Sponsor -provided electronic device. 
Subjects will receive notifications reminding them to complete the weekly KOOS -PS 
assessment.  
Patient Global Assessment of Disease Activity  
The Patient Global Assessment is a 50 mm visual analog scale (VAS) on which the subject s will 
rate how well they are doing, considering all the ways in which illness and health conditions may 
affect them . The VAS will be anchored by [CONTACT_168969]  (“Very Well” on the left and 
“Very Poorly” on the right).  The Patient Global Assessment will be completed by [CONTACT_168970] (between 5:00 pm and 11:59 pm)  remotely on their electronic devices  on Screening  
Visit 2 + 5 days ( or up until the day before the Day 1 visit ). After Day 1, monthly  (every 4 
weeks)  Patient Global Assessments will be completed by [CONTACT_168968]  (between 
5:00 pm and 11:59 pm)  remotely on their electronic devices . Refer to Section 7.3.[ADDRESS_197156]’s disease activity independent of the patient’s self -assessment. The VAS will be 
anchored by [CONTACT_168969] (“Very Good” on the left and “Very Bad” on the right).  The 
Physician Global Assessment will be performed on paper  at Day 1  and Weeks 4, 12, and 24 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   37 (EOS)/ET .  
The Investigator completing the Physician Global Assessment must sign/initial and date the 
source document to indicate that the assessment is reported accurately. A study staff member 
will record the Physician Glob al Assessment score in the eCRF. The score is determined by 
[CONTACT_23808] (mm) between the “Very Good” anchor and the Investigator’s mark, 
providing a range of scores from 0 to 100.  
The Physician  Global Assessment of Disease Activity questionnaire s will be provided by [CONTACT_168971].   
Evaluation of Success of Blinding  
At Day 1 (post  intra-articular injection) and Week 24 (EOS)/ET , subjects will complete a 
questionnaire on paper as to which treatment arm of the study they bel ieve they were assigned to 
in order to evaluate the effectiveness of blinding. The questionnaire will capture responses of 
“Study drug injection,” “Injection of 2 mL inactive vehicle substance,” “ Needle insertion into the 
knee with no vehicle substance inj ected,” and “Do not know.”  
7.1.[ADDRESS_197157] of care study procedures are not required by [CONTACT_3181].  
7.2 LABORATORY PROCEDURES/EVALUATIO NS 
7.2.1  CLINICAL LABORATORY EVALUATIONS  
Non-fasting samples for clinical laboratory analysis  by [CONTACT_168972] a qualified staff member at Screening Visit  1 and Week s 4, 12, and 24 (EOS)/E T. At 
a minimum,  the following tests will be conducted:  
• Chemistry panel:  Albumin, alkaline phosphatase ( ALP ), alanine aminotransferase 
(ALT ), aspartate aminotransferase ( AST ), blood urea  nitrogen , bicarbonate, calcium 
(corrected total), chloride, creatinine, glucose, lactate dehydrogenase (LDH), 
potassium, sodium, bilirubin  (total)  
• Hematology:  Hemoglobin, hematocrit, red blood cell (RBC) count, white blood cell 
(WBC) count with differential, and p latelet count  
• Urinalysis:  Clarity, specific gravity, pH, protein, glucose, ketones, nitrite, leukocytes, 
and occult  blood   
An HbA1c test will be p erformed on all subjects at Screening Visit  1. 
Urine microscopy will be performed if urinalysis urine protein,  leukocyte esterase (WBC 
esterase) , occult blood, or nitrites values are out of range , or if the Investigator deems that the 
microscopy is clinically warranted.  
The Investigator  or the Investigator ’s designee must review the results of each subject’s 
Scree ning Visit  [ADDRESS_197158] not be 
randomized on Day 1  and, if results are available for review prior to Screening Visit 2, is not 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   38 recommended to proceed to  Screening Visit 2  if any of the Screen ing Visit  1 results are outside 
the normal range for the laboratory AND, in the opi[INVESTIGATOR_689] , are clinically 
significant.  
The results of the clinical laboratory tests will be reported on the laboratory’s standard reports.  
The Investigator  must review all laboratory reports in a timely manner, noting “not clinically 
significant” (NCS) or comment on the clinical significance (clinically significant:  yes/no) of any 
result that is outside the normal range for the laboratory or has a toxicity g rade of [ADDRESS_197159] will 
include: cocaine , opi[INVESTIGATOR_2438], methamphetamine, amphetamine, phencyclidine, barbiturates, 
methadone, oxycodone, and ecstasy . Results from the drug test will be utilized t o determine 
subject eligibility . 
7.2.[ADDRESS_197160]’s source 
record.  After written informed consent is obtained, the subject will be assigned a subject number.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   39 The following procedures and assessments will be performed 10-22 days prior to Day 1 : 
• Documentation of demographic information, including date of birth, gender, race, and 
ethnicity  
• Documentation of current and past medical history  including assistive device usage , 
documentation of current medications, and review of prior medication excluded  by 
[CONTACT_760]  
• Physical examination , including knee examination  of both knees  and selection of 
target knee  
• Vital signs measurements (pulse, blood pressure, respi[INVESTIGATOR_1487], and temperature)  
• Height and weight measurements  
• Venipuncture and collection of s amples for clinical laboratory tests  
• Pregnancy test ( serum -based)  
• Urine drug  test  
• WPI&SS assessment  
• Radiograph – bilateral in weight -bearing  fixed flexion position , posterior -anterior 
(PA) view  X-ray 
Results from these evaluations will be compared with in clusion/exclusion criteria to determine 
subject eligibility.  In order to complete randomization, WPI&SS scores and subject 
bilateral/unilateral OA of the knee status from Screening Visit [ADDRESS_197161]  3 days after Screening Visit 1 and between 7 to 12 days (inclusive)  
prior to Day 1.   
This visit should occur after confirmation of eligible pregnancy test (if applicable), radiograph, 
clinical laboratory, and urine  drug test report results .  
The following procedures and assessments will be performed at Screening Visit 2:  
• Electronic diary device provision and  subject  training  for electronic  diary and  
questionnaire completion  
Starting on the day of Screening Visit 2,  after the site visit, s ubject s will begin  completion of 
daily pain NRS  assessments  and NSAIDs electronic diary completion  remotely on their 
electronic devices  in the evening ( between 5:00 pm and 11:59  pm). 
 
Note:  On Screening Visit 2 + 5 days ( or up until  the day before the Day 1 visit ), subjects will 
complete the WOMAC, KOOS, KOOS -PS, and Patient Global Assessment , in addition to the 
pain NRS assessment  and NSAIDs electronic diary , in the evening (between 5:00 pm and 11:59 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   40 pm) remotely on their electronic  devices . Refer to Section 7.3.[ADDRESS_197162] occur within 10 to 22 days of Screening Visit  1. Subjects with a  period of more 
than 12 days between Screening Visit 2 and Day 1 are to be screen failed due to the lengthened 
time between baseline questionnaires and study medication injection.  
The following procedures a nd assessments will be performed at Day 1 prior to randomization:  
• Review and/or documentation  of current and past medical history, documentation of 
current medications, and review of prior medication excluded by [CONTACT_760]  
• Physical examination , including  knee examination of both knees  
• Vital signs measurements (pulse, blood pressure, respi[INVESTIGATOR_1487], and temperature)  
• Review of pain NRS electronic diary compliance from Screening Visit 2 to Day 1  
• Electronic questionnaire review ( WOMAC)  
Results from these ev aluations will be compared with inclusion/exclusion criteria to determine 
subject eligibility.  
Physician Global Assessment will also be performed prior to randomization ; however, results 
from this assessment  do not determine eligibility . 
The following randomization cohorts will be available until the associated subject counts are 
reached:  
• Unilateral OA with WPI ≤ 4 and SSQ2 ≤ 2 – 240 subjects  
• Bilateral OA with WPI ≤ 4 and SSQ2 ≤ 2 – 240 subjects  
• Unilateral OA with WPI > 4 and/or SSQ2 > 2 – 60 subjects  
• Bilateral OA with WPI > 4 and/or SSQ2 > 2 – [ADDRESS_197163] to be eligible for randomization, WPI&SS scores and subject 
bilateral/unilateral OA of the knee status from Screening Visit [ADDRESS_197164] be entered into EDC prior 
to the study reaching the enrollment caps described above.  
The following procedures and assessments will be performed at Day 1 following randomization:  
• Intra -articular study medication injection (or placebo)  
• Collection of TEAE and concomitant procedures/ medication data  
• Evaluation of success of blinding   
Note:  After the Day 1 site visit , subjects will complete monthly (every 4 weeks) WOMAC, 
KOOS, and Patient Global Assessment , weekly (every 7 days)  KOOS -PS, and daily pain NRS 
and NSAIDs electronic diary completion  in the evening (between 5:00 pm and 11:59 pm)  
remotely on their electronic devices . Refer to Section 7.3.7  for a schedule of electronic diary and 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   41 questionnaire completion.  
7.3.3  FOLLOW -UP  
Week 4 and Week 1 2 
The Week 4 and Week 1 2 visits should occur on Day 29 (with a window of +  3 days) and Day 
85 (with a window of +  3 days), respectively .  
The following procedures and assessments will be performed at each of these visits : 
• Collection of TEAE and concomitant procedures/ medication data  
• Physical examination, including knee examination of both knees  
• Vital signs measurements (pulse, blood pressure, respi[INVESTIGATOR_1487], and temperature)  
• Venipuncture and collection of samples for clinical laboratory tests  
• Physician Global Assessment  
7.3.4  FINAL STUDY VISIT  
Week 24 End of Study (EOS)  
This final study  visit should occur on Day 169 with a window of + 7 days.  
The following procedures and assessments will be performed at Week 24 (EOS):  
• Collection of TEAE and concomitant procedures/therapi[INVESTIGATOR_014]/medication data  
• Review of medical history  
• Vital signs measurement s (pulse, blood pressure, respi[INVESTIGATOR_1487], and temperature)  
• Physical examination, including knee examination of both knees  
• Weight measurement  
• Venipuncture and collection of samples for clinical laboratory tests  
• Radiograph  – bilateral in weight -bearing fix ed flexion position, posterior -anterior 
(PA)  view  X-ray 
• Physician Global Assessment  
• Evaluation of success of blinding  
• Return of electronic device  
7.3.[ADDRESS_197165] premature withdrawal or termination : 
• Collection of TEAE and concomitant procedures/therapi[INVESTIGATOR_014]/medication data  
• Review of medical history  
• Vital signs measurements (pulse, blood pressure, respi[INVESTIGATOR_1487], and temperature)  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   42 • Physical examination, including knee examination of both knees  
• Weight measurement  
• Venipuncture and collection of samples for clinical laboratory tests  
• Radiograph  – bilateral in weight -bearing fixed flexion position, posterior -anterior 
(PA) view  X-ray 
• Physi cian Global Assessment  
• Evaluation of success of blinding  
• Return of electronic device  
 
7.3.6  SCHEDULE OF EVENTS TABLE  
 
Procedure  Screening Perioda 
(Days -22 to -1) Day 1b Week 4  
(Day 29  
+3 days)  Week 12  
(Day 8 5 
+3 days)  Week 24  
(EOS)  
(Day 1 69 +7 
days)  / ET Screening Visit 1  
(Days -22 to -10) Screening Visit 2  
Days (-12 to -7) 
Informed consent  X      
Inclusion & exclusion 
criteria  X  X    
Demographics  X      
Medical history  X  X   Xc 
Current and prior 
procedures/medications  X  X    
Serum pregnancy test X      
Radiograph  X     X 
Physical exam ination  X  X X X X 
Knee examination  X  X X X X 
Selection of target knee  X      
Height  X      
Weight  X     X 
Vital sign s X  X X X X 
Clinical laboratory 
sampling  X   X X X 
Urine  drug test  X      
Electronic diary and 
questionnaire trainingd  X (eDiary device 
provision  and 
training)      
WPI&SSe X      
Pain NRSf   X (Review)     
WOMACg   X (Review)     
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   43 Procedure  Screening Perioda 
(Days -22 to -1) Day 1b Week 4  
(Day 29  
+3 days)  Week 12  
(Day 8 5 
+3 days)  Week 24  
(EOS)  
(Day 1 69 +7 
days)  / ET Screening Visit 1  
(Days -22 to -10) Screening Visit 2  
Days (-12 to -7) 
Physician Global 
Assessment    X X X X 
Randomization    X    
Intra -articular injection    X    
TEAEs and concomitant 
procedures/ medication s   X X X X 
Evaluation of success of 
blinding    X   X 
Return of electronic 
device       X 
a The screening period is a minimum of 10 days and a maximum of 22 days and includes Screening Visit 1 and Screening 
Visit 2; Screening Visit [ADDRESS_197166] (if applicable), radiograph, clinic al laboratory, and urine drug  test report 
results . 
b At Day 1, all procedures  should be performed prior to study medication injection except for collection of TEAE and 
concomitant procedures/ medication data  and the evaluation of success of blinding . 
c Review medical history to capture End Date(s), if applicable, of any ongoing medical history(ies) collected at screening . 
d Electronic diary devices will be provided to subjects at Screening Visit 2; subject electronic diary and questionnaire 
training will  be conducted at Screening Visit 2 . 
e WPI&SS will be administered on site at Screening Visit 1. 
f Electronic diary compliance for daily pain NRS over the screening period will be reviewed at Day [ADDRESS_197167] eligibility.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   44 7.3.7  SCHEDULE OF ELECTRON IC DIARY AND QUESTIONNAIRE COMPLE TION TABLE  
 
 Monthly WOMAC, KOOS, and 
Patient Global Assessment  Weekly KOOS -PS Daily pain NRS and  
NSAIDs electronic diary  
Study Visit or Day  
 WOMAC, KOOS, and Patient Global 
Assessment will be completed by 
[CONTACT_168973] 2 + 5 days 
(or up until the day before the Day 1 
visit) and monthly in the evening 
(between 5:00 pm and 11:59 pm)  
remotely on their electronic devices . 
Monthly ques tionnaires should be 
performed in the 2 days prior to each 
month (4 weeks) as outlined below.  KOOS -PS will be completed by 
[CONTACT_168973] 2 + 5 days 
(or up until the day before the Day 1 
visit) and weekly in the evening 
(between 5:00 pm and 11:59 pm)  
remotely on their electronic devices . 
KOOS -PS should be performed in the 
2 days prior to each week as outlined 
below.  Pain NRS and NSAIDs electronic 
diary should be completed daily 
starting after Screening Visit 2. 
Subjects will complete the dia ry in the 
evening (between 5:00 pm and 11:59 
pm) remotely on their electronic 
devices . Diary completion should 
occur every day including on study 
visit days.  
Screening Visit 1        
        
Screening Visit 2        
      Complete daily starting on the same 
day of Screening Visit 2 (after the 
visit); pain NRS assessments are to be 
completed for each knee.  
Screening Visit 2 + 5 days Baseline monthly questionnaires  
(or up until the day before the  
Day 1 visit ) Baseline weekly questionnaire  
(or up until the day before the  
Day 1 visit )   
        
Day 1      
    Complete on Day 6 or 7  Starting on the same day of Day 1 
(after the visit), pain NRS assessments 
are to be completed for the target knee 
only.   
  Week 1 (Day 8)      
    Complete on Day 13 or 14  
Week 2 (Day 15)      
    Complete on Day 20 or 21    
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   45  Monthly WOMAC, KOOS, and 
Patient Global Assessment  Weekly KOOS -PS Daily pain NRS and  
NSAIDs electronic diary  
Week 3 (Day 22)       Complete daily  
  Complete on Day 27 or 28  Complete on Day 27 or 28    
Week 4 (Day 29)  Questionnaires should NOT be completed on same day as a study visit.    
    Complete on Day 34 or 35    
Week 5 (Day 36)        
    Complete on Day 41 or 42    
Week 6 (Day 43)        
    Complete on Day 48 or 49    
Week 7 (Day 50)        
  Complete on Day 55 or 56  Complete on Day 55 or 56    
Week 8 (Day 57)        
    Complete on Day 62 or 63    
Week 9 (Day 64)        
    Complete on Day 69 or 70    
Week 10 (Day 71)        
    Complete on Day 76 or 77    
Week 11 (Day 78)        
  Complete on Day 83 or 84  Complete on Day 83 or 84    
Week 12 (Day 85)  Questionnaires should NOT be completed on same day as a study visit.    
    Complete on Day 90 or 91    
Week 13 (Day 92)        
    Complete on Day 97 or 98    
Week 14 (Day 99)        
    Complete on Day 104 or 105    
Week 15 (Day 106)        
  Complete on Day 111 or 112  Complete on Day 111 or 112    
Week 16 (Day 113)        
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   46  Monthly WOMAC, KOOS, and 
Patient Global Assessment  Weekly KOOS -PS Daily pain NRS and  
NSAIDs electronic diary  
    Complete on Day 118 or 119   Complete daily  
Week 17 (Day 120)        
    Complete on Day 125 or 126    
Week 18 (Day 127)        
    Complete on Day 132 or 133    
Week 19 (Day 134)        
  Complete on Day 139 or 140  Complete on Day 139 or 140    
Week 20 (Day 141)        
    Complete on Day 146 or 147    
Week 21 (Day 148)        
    Complete on Day 153 or 154    
Week 22 (Day 155)        
    Complete on Day 160 or 161    
Week 23 (Day 162)        
  Complete on Day  167 or 168  Complete on Day 167 or 168    
Week 24 (Day 169)  Questionnaires should NOT be completed on same day as a study visit.    
 
 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   47 7.4 JUSTIFICATION FOR SE NSITIVE PROCEDURES  
Not applicable for this study.  
7.5 CONCOMITANT MEDICATI ONS, TREATMENTS, AND PROCEDURES  
Details regarding the name, indication, route of administration, dose, and frequency of all 
medications taken within 30 days prior to Screening Visit 1 through Week 24 (EOS)/ET  will be 
recorded in the eCRF. “All medications” should include prescription, over the counter, 
supplements, as well as herbal or alternative medications.  Subjects  with a “yes” response for 
daily NSAID usage in their electronic diary should have a corresponding NSAID recorded in the 
eCRF.  
Procedures  or non -drug therapi [INVESTIGATOR_168896], new, or modified at or after the Screening 
Visits must be recorded on the “Procedures and Non -Drug Therapi[INVESTIGATOR_014]” page of the eCRF.  
Any new or modified concomitant therapy must be considered to determine if it is related to a  
TEAE .  
7.5.1  PRECAUTIONARY MEDICA TIONS, TREATMENTS, A ND PROCEDURES  
Not applicable to this study.  
7.6 PROHIBITED MEDICATIO NS, TREATMENTS, AND PROCEDURES  
Prohibited Concomitant Medications  and Procedures : 
• Any i ntra-articular injection , including  glucocorticoids , hyaluronic acid derivatives , 
PRP, stem cell therapi[INVESTIGATOR_014], or other agents with therapeutic intent , into either knee is 
prohibited while the subject is on study ; intra -articular injection of glucocorticoids , 
hyaluronic acid derivatives,  PRP, stem cell s, or other therapeu tic agents into joints 
other than the knee is allowed.  
• The following medications a re prohibited while the subject is on study:  
 Opi[INVESTIGATOR_2438] ; short-term use of opi[INVESTIGATOR_168897]  
 Centrally ac ting analgesics (e.g., duloxetine)  (refer to Appendix 2 )  
 Other anticonvulsants not listed in Appendix 2  are also prohibited unless used f or 
seizure or migraine prophylaxis  
 Systemic glucocorticoids  greater than 10 mg of prednisone per day or the 
equivalent   
 Drugs of abuse except alcohol and marijuana  
• Electrotherapy  (refer to Appendix 2 ), acupuncture , and/or chiropractic treatments  for 
knee OA are prohibited while the subject is on study . 
• Any new f ormalized (i.e., prescri bed by a medical professional) physical therapy 
exerci se programs  for knee OA are prohibited while the subject is on study ; 
continuation of formalized physical therapy exercise program s that are already in 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   48 progress at the time of screening are allowed . 
• Planned or elective surgery, including arthroscopy, is pr ohibited while the subject is 
on the study.  Non-surgical invasive procedures conducted for a diagnostic or 
therapeutic purpose that are scheduled during the study period are not prohibited. 
Examples include, but are not limited to: endoscopy, colonoscopy, bronchoscopy, 
cystoscopy, radiologic procedures such as coronary artery catheterization with or 
without intervention, and non -surgical cosmetic procedures such as Botox  or other 
cosmetic  injections.  
• Subjects are prohibited from participating in any other clinical research trial that 
include s the receipt of an investigational product or any experimental therapeutic 
procedure . Subjects are also prohibited from participating in  any observational 
research  trial related to osteoarthritis  while on study.  
The Investigator  should notify the Samumed Medical Monitor  immediately if any prohibited 
therapi[INVESTIGATOR_168898] .  
7.7 PROPHYLACTIC MEDICAT IONS, TREATMENTS, AN D PROCEDURES  
Not applicable  to this study.  
7.8 RESCUE MEDICATIONS, TREATMENTS, AND PROC EDURES  
Not applicable to this study.  
7.9 PARTICIPANT ACCESS T O STUDY AGENT AT STU DY CLOSURE  
Not applicable to this study.  
8. ASSESSMENT OF SAFETY  
8.1 SPECIFICATION OF SAF ETY PARAMETERS  
Safety assessments include physical examinations, vital signs, clinical laboratory tests, 
solicitation of TEAEs and concomitant medications, and general medical evaluations .  
8.1.1  DEFINITION OF ADVERS E EVENTS  (AE)  
TEAEs  in the eCRF will be classified according to the most recent US FDA definitions and in a 
manner consistent with ICH guidelines. As such the following definitions will be used:  
An adverse event (AE) is any unfavorable and unintended sign, symptom, or diseas e temporally 
associated with the use of an investigational (medicinal) product (IP) or other protocol -imposed 
intervention, regardless of attribution.  An AE may include intercurrent illnesses or injuries that 
represent an exacerbation (increase in frequenc y, severity, or specificity) of preexisting 
conditions (e.g., worsening of asthma).   
Whenever possible, it is preferable to record a diagnosis as the TEAE term rather than a series of 
symptoms relating to a diagnosis. In order to classify TEAEs and disease s, preferred terms will 
be assigned by [CONTACT_168974], using the Medical 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   49 Dictionary for Regulatory Activities (MedDRA).   
8.1.2  DEFINITION OF SERIOU S ADVERSE EVENTS  (SAE)  
According to the ICH Guidelines for Good Clinical Pr actice (E6), an SAE is any untoward 
medical occurrence during the course of a clinical investigation that is characterized by 1 or 
more of the following:  
• Results in death  
• Is life threatening  
• Requires nonscheduled (not routine or planned) subject hospi[INVESTIGATOR_168899] ≥ 24 hours and admission to the hospi[INVESTIGATOR_307]  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Is an important medical event, defined as an event that does not fit one of the other 
outcomes, but may jeopardize the subject and may require medical or surgical 
intervention (treatment) to prevent one of the other outcomes. Examples include 
allergic bronchospasm (a serious problem with breathing) requiring treatment i n an 
emergency room, serious blood dyscrasias (blood disorders), or seizure/convulsion 
that does not result in hospi[INVESTIGATOR_059]. The development of drug dependence or drug 
abuse would be other examples of important medical events.   
All SAE information must be recorded on the SAE form approved by [CONTACT_1034]. Additional 
follow -up information (e.g., test results, autopsy, and discharge summary) may be requested to 
supplement the SAE report form and can be attached as de -identified records.  
8.1.3  DEFINITION OF UNANTI CIPATED PROBLEMS  (UP)  
An unanticipated problem is defined as, in general, any incident, experience, or outcome that 
meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are descr ibed in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the participant 
population being studied;  
• Related or possibly related to participation in the research (“possi bly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
8.2 CLASSIFICATION OF AN  ADVERSE EVENT  
8.2.1  SEVERITY OF EVENT  
The Investigator  will assess TEAEs for severity utilizing the “Guidance for Industry: Toxicity 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials”. This 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   50 toxicity scale is presented in Appendix 1 . Laboratory values not listed on the tox icity scale will 
be assessed for severity by [CONTACT_168975] . 
8.2.2  RELATIONSHIP TO STUD Y AGENT  
The relations hip of the study treatment to a TE AE will be determined by [CONTACT_168976]:  
1.  Not Related  
The TEAE is not related if (1) exposure to the investigational product (or placebo) or 
administration of the study injection has not occurred or (2) the occurrence of the TEAE is not 
reasonably related in time or (3) the TEAE is considered related to another eve nt or product not 
associated with the investigational product (or placebo) or the study injection.  
2.  Unlikely Related  
The TEAE is unlikely related if (1) the TEAE is unlikely related in time or (2) the TEAE is 
considered unlikely to be related to use of the investigational product (or placebo) or study 
injection (i.e., there are no facts [evidence] or arguments to suggest a causal relationship).  
3.  Possibly Related  
The TEAE is possibly related if (1) the investigational product (or placebo) or the study injection 
and TEAE are considered reasonably related in time and (2) the TEAE could be explained by 
[CONTACT_168977] (or placebo) or administration of the 
study injection.  
4.  Probably Related  
Exposure to the invest igational product (or placebo) or administration of the study injection and 
TEAE are probably related if (1)  the investigational product (or placebo) or study injection and 
TEAE are considered reasonably related in time and (2) the investigational product (or placebo) 
or study injection is more likely than other causes to be responsible for the TEAE or is the most 
likely cause of the TEAE. 
8.2.3  EXPECTEDNESS  
The Sponsor will be respons ible for determining whether a TE AE/S AE is expected or 
unexpected. A  TEAE/SAE will be considered unexpected if the nature, severity, or frequency of 
the event is not consistent with the risk information previously described for the study agent in 
the IB or is not listed in the IB at the specificity or severity that has been observed.  
8.[ADDRESS_197168]’s last visi t will be followed until the 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   51 study close -out visit, if requested . Serious adverse events that are not resolved or stabilized 
during this time period will be followed unt il resolution or stabilization.  
8.4 REPORTING PROCEDURES  
8.4.1  ADVERSE EVENT REPORT ING  
The Inves tigator is responsible for reporting TEAEs to the Sponsor and IRB according to the 
protocol as well as  21 Code of Federal Regulations (CFR) part 50, part 56, and part 312. The 
Investigator is responsible for ensuring accurate TEAE information is reviewed a nd recorded in 
the subject source and the TEAE eCRF in a timely manner.  The Sponsor is responsible for 
submitting reports of TEAEs associated with the use of study medication that are both serious 
and unexpected to the FDA according to 21 Code of Federal R egulations (CFR) 312.32. All 
Investigator s participating in ongoing studies with the study medication will receive copi[INVESTIGATOR_168900]/EC according to their 
institution’s requirements.   
8.4.2  SERIOUS ADVERS E EVENT REPORTING  
The Investigator is responsible for reporting SAEs to the Sponsor and IRB according to 21 Code 
of Federal Regulations (CFR) part 50, part 56, and part 312. The Investigator and Samumed will 
manage SAEs according to the study document “Guidelines For The Management Of Serious 
Adverse Events (SAEs) And Pregnancies ”. 
All SAEs must be reported as described in the study manual by [CONTACT_737] , Study 
Coordinator, other designated study personnel, or Clinical Research Associate within 24 hours  of 
notification of the SAE. The Investigator  or designee  should  submit the SAE report to the 
Samumed Study SAE email address: [EMAIL_3381]  or FAX: +[PHONE_3685].  Follow -up 
information must be  detailed in  a follow -up SAE report and  reported to the Samumed Study SAE 
email address or fax number as it becomes available. The Investigator  also must report all SAEs 
promptly to the appropriate IRB/EC as required by [CONTACT_8236]. Sponsor contact [CONTACT_168978]  1. 
Table  1: Sponsor Contact [CONTACT_168979]  
  
      
      
      
8.4.3  UNANTICIPATED PROBLE M REPORTING  
Incidents or events that meet the criteria for unanticipated problem require the creation and 
completion of an UP report. It is the site investigator’s responsibility to report UPs to their IRB 
and to the Sponsor. The UP report will include the following information:  

Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   52 • Protocol identifying information: protocol title and number, PI’s name, and the IRB 
project number;  
• A detailed description of the event, incident, experienc e, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UP; and 
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP.  
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline:  
• UPs that are SAEs wil l be reported to the IRB and to the Sponsor  within 24 hours of the 
investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the Sponsor  within the IRB -required 
reporting timeframe .  
• All UPs should be reported to appropriat e institutional officials (as required by [CONTACT_8706]’s written reporting procedures) and IRB within the timeframe  specified  by [CONTACT_168980].   
8.4.[ADDRESS_197169]  
Not applicable to this study.  
8.4.5  REPORTING OF PREGNAN CY  
Although pregnancy is not a formal SAE, if a study participant or the partner of a study 
participant becomes pregnant while the study participant is on study, the pregnancy is to be 
reported via SAE  reporting procedures . The Investigator and Samumed will m anage reporting of 
pregnancies according to the study document “Guidelines For The Management Of Serious 
Adverse Events (SAEs) And Pregnancies ”. 
8.5 STUDY HALTING RULES  
Not applicable to this study.  
8.6 SAFETY OVERSIGHT  
Clinical safety oversight will be performed  by [CONTACT_168981] . In addition, on -site review will be conducted by 
[CONTACT_108672].  
9. CLINICAL MONITORING 
All aspects of the study will be monitored by [CONTACT_57756]’s designees with 
respect to current Good Clinical Practice (GCP) and Standard Operating Procedures (SOPs) for 
compliance with applicable government regulations. It is the responsibili ty of the Investigator  to 
provide all study records, including eCRFs and source documents among other records, for 
review and inspection by [CONTACT_24653].  
Clinical monitoring will be performed per the Clinical Monitoring Plan. Clinical monitors will  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   53 periodically evaluate the progress of the study, including the verification of appropriate consent 
form procedures and the verification of the accuracy and completeness of eCRFs. Clinical 
monitors will also ensure that all protocol requirements, applicabl e US FDA regulations, other 
regulatory  requirements, and the Investigator ’s obligations are being fulfilled . 
Centralized data monitoring will be performed per the Centralized Data Monitoring Plan in order 
to periodically evaluate study progress and risks. A regular report of risks will be utilized 
together with on -site and off -site centralized data  monitoring to direct overall monitoring focus 
and activities to the areas of greatest risk which have the most potential to impact subject safety 
and data qualit y. 
The accuracy of the data will be verified by [CONTACT_168982] 11. 
10. STATISTICAL CONSIDER ATIONS   
10.1 STATISTICAL AND ANAL YTICAL PLANS  
This section describes the planned statistical analyses in general terms. A complete description of 
the statistical analyses will be specified in a statistical analysis plan (SAP), finalized p rior to 
database lock.    
10.2 STATISTICAL HYPOTHES ES 
No formal hypotheses are being tested in this study.  
10.3 ANALYSIS DATASETS  
Full Analysis Set  (FAS) : All subjects who are randomized  and receive a study injection . Full 
analysis set is used to describe the analysis set which is as complete as possible and as cl ose as 
possible to the intent -to-treat ideal of  including all randomized subjects.  
Modified Full Analysis Set  (mFAS) : FAS subjects who receive a protocol specified injection. 
Subjects who are administered a treatment that is not prescribed by [CONTACT_168983].  
Per-Protocol Analysis Set  (PPAS) : mFAS  subjects who  complete the study  and d o not have 
any major protocol deviations.  
Safety Analysis Set  (SAS) : All subjects who  receive a study injection . 
10.[ADDRESS_197170] deviation (SD), 
median, minimum , and maximum will be reported. All categorical endpoints will be summarized 
using fr equencies and percentages.  
10.4.2  ANALYSIS OF THE PRIM ARY ENDPOINT(S)  
Analysis of covariance (ANCOVA) will be used to estimate the l east squares difference in the 
change in weekly average of daily pain NRS, WOMAC Pain, WOMAC Function, and medial 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   54 JSW  adjusting for baseline value . Change will be assessed from baseline between each treatment 
group and the vehicle placebo group. Unadjusted  95% confidence intervals and P values will be 
reported.  
Multiple Comparison Procedure  Modelling (MCP -Mod) will estimate SM04690  dose response 
compared to vehicle using the results of the primary efficacy endpoint analyses .  
As the study  is stratified bas ed upon known clinical phenotypes of OA, a ll primary efficacy 
analyses will be completed in three subject  populations: 1) subjects with unilateral symptomatic 
OA, 2) subjects with unilateral symptomatic OA and without widespread pain ( WPI ≤ 4 and 
SSQ2 ≤ 2 ), and 3) all subjects.  
10.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
The number and percent of subjects experiencing TEAEs will be summarize d by [CONTACT_12917], 
severity, and relationship for each treatment group.  
ANCOVA will be used to estimate the least squares difference in the change in Patient Global 
Assessment a djusting for baseline value. Change will be assessed from baseline between each 
treatment group and the vehicle placebo group. Unadjusted 95% confidenc e intervals and P 
values will be reported.  
MCP -Mod will estimate SM04690  dose response compared to vehicle using the results of the 
secondary efficacy  endpoint analyses.  
As the study is stratified based upon known clinical phenotypes of OA, all secondary  efficacy  
analyses will be completed in three subject populations: 1) subjects with unilateral symptomatic 
OA, 2) subjects with unilateral symptomatic OA and without widespread pain ( WPI ≤ 4 and 
SSQ2 ≤ 2 ), and 3) all subjects.  
10.4.[ADDRESS_197171] 
value recorded for any given parameter prior to study medication injection at Day 1 . 
10.4.6  PLANNED INTERIM ANAL YSES  
Not applicable to this study.  
 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   55 [IP_ADDRESS] SAFETY REVIEW  
Medical monitoring of study safety assessment data will be performed during periodic safety 
reviews detailed in the Medical Monitoring Plan . 
[IP_ADDRESS] EFFICACY REVIEW  
Not applicable to this study .  
10.4.7  EXPLORATORY ANALYSES  
Change from baseline will be summarized with descriptive statistics at Weeks 4, 8, 12, 16, and 
20 for WOMAC pain subscore , WOMAC function subscore,  and Patient Global Assessment ; at 
Weeks 4, 8, 12, 16, 20 , and 24 for WOMAC total score , and KOOS  (five subscales  [Pain, 
Symptoms, ADL, Sport/Rec and QOL ] as well as aggregate scores KOOS 4 and KOOS 5); and at 
Week s 4, 12, and 24  for Physician Global Assessment. Change from baseline will also be 
statistically describe d for weekly KOOS -PS and weekly averages of daily pain NRS  (aside from 
Week 24) . Change over time  in weekly NSAID usage will also be assessed at every week . 
ANCOVA will be used to estimate the least squares difference in the change from baseline in 
exploratory outcomes between each of the four active treatment groups and the vehicle group , 
adjusted for baseline value. Additionally, ANCOVA will be used to estim ate the least squares 
difference in the change from baseline in all outcomes  (including primary and secondary)  
between the vehicle group  and the sham group , adjusted for baseline value. Unadjusted 95% 
confidence intervals and P values will be reported.  
MCP-Mod will estimate SM04690  dose response compared to vehicle using the results of the 
exploratory efficacy endpoint analyses.  
As the study is stratified based upon known clinical phenotypes of OA, all exploratory efficacy 
analyses will be completed in th ree subject populations: 1) subjects with unilateral symptomatic 
OA, 2) subjects with unilateral symptomatic OA and without widespread pain ( WPI ≤ 4 and 
SSQ2 ≤ 2 ), and 3) all subjects.  
Evaluation of subject awareness of randomized treatment given  and the success of blinding in 
this trial will be estimated using an appropriate categorical analysis. Specifically, the percentage 
of subjects accurately identifying the assigned treatment group will be estimated.  
10.4.8  ADDITIONAL SUB -GROUP  ANALYSES  
Efficacy analyses de scribed in Section 10.4.2  and Section 10.4.7  will be f urther analyzed by 
[CONTACT_168984], complementary clinical phenotypes of OA not already defined in the primary 
analysis . Details on these sub-group analyse s will be provided in the SAP.  
The additional clinical phenotypes of OA will include, but are not limited to:  
• Bilateral Symptomatic OA  
• WPI ≤ 4 and SSQ2 ≤ 2  
• WPI > 4 and/or SSQ2 > 2  
• Unilateral Symptomatic OA with WPI > 4 and/or SSQ2 > 2  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   56 • Bilateral Symptomatic OA with WPI ≤ 4 and SSQ2 ≤ 2  
• Bilateral Symptomatic OA with WPI > 4 and/or SSQ2 > 2  
10.5 SAMPLE SIZE  
A sample size of approximately 630 subjects will be randomized at a ratio of 1:1:1:1 :1:1 (0.03 
mg active per 2 mL injection : 0.07 mg active per 2 mL injection : 0.15 mg active per 2 mL 
injection : 0.23 mg activ e per 2 mL injection : 0.0 mL vehicle  : 2.0 mL vehicle ). The sample size 
for this study was based upon accepted dose finding statistical practice  (Ting et al. 2017 ). 
10.[ADDRESS_197172] identify unblinded personnel who wi ll be responsible for preparing 
the appropriate dilution of the study medication and who are able to perform the injection  of 
study medication and/or vehicle . Study personnel administering or preparing study medication 
and reference therapy must minimize a ny contact [CONTACT_168985] . Each site will be 
required to document a blinding plan that identifies the blinded and unblinded personnel at the  
investigational center  and describes how the study blind will be maintained.  
Subjects will be assigned a s ubject  number at their Screening Visit  1. On Day 1, eligible subjects 
will be randomized via the Medidata database.  Upon randomization of a subject, a Treatment 
Arm Notification email will be sent from [EMAIL_3382]  to the unblinded investigational 
staff member  designated in the Site-Specific  Blinding Plan. Subjects will be randomized 
1:1:1:1 :1:1 (0.03 mg ac tive per 2 mL injection  : 0.07 mg active per 2 mL injection  : 0.15 mg 
active per 2 mL injection  : 0.23 mg active per 2 mL injection  : 0.0 mL vehicle  : 2.0 mL vehicle ) 
to each treatment  group using a permuted block design stratified by [CONTACT_168986] (50% bilateral, 50% unilateral) and WPI &SS (80% WPI ≤ 4 and SSQ2 ≤ 2, 20% WPI > 4 
and/or SSQ2 > 2) . Specific information regarding the use of Medidata Balance to store and 
implement the permuted block design will be detailed within the SAP. 
10.6.2  EVALUA TION OF SUCCESS OF B LINDING  
Subjects will be queried regarding the perceived effectiveness of blinding . Details of this 
analysis will be provided in the SAP . 
10.6.3  BREAKING THE STUDY B LIND/ PARTICIPANT  CODE  
The blind may be broken by a qualified physician who is an Investigator in this study in the 
event of a medical emergency in which knowledge of the identity of the study medication is 
critical to the management of the subject’s immediate course of treatmen t. Before breaking the 
blind, the Investigator should determine that the information is necessary (i.e., that it will alter 
the subject’s immediate course of treatment).  
If deemed necessary to break the blind for a study subject, the Samumed Medical Monit or is to 
Protocol SM04690 -OA-[ADDRESS_197173].  
11. SOURCE DOCUMENTS AND  ACCESS TO SOURCE DA TA/DOCUMENTS  
The Investigator  must maintain required records for all study subjects. Source data are all 
information, original records of clinical findings, observations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial.  Source d ata for this study will be 
recorded in the subject's source document s and on the eCRFs. All data on these eCRFs should be 
recorded completely and promptly. A copy of the completed eCRFs for each subject will be 
retained by [CONTACT_118250].  
The Inves tigator  must maintain adequate and accurate source documents upon which eCRFs for 
each subject are based. They are to be separate and distinct from eCRFs, except for cases in 
which the Sponsor has predetermined that direct data entry into specified pages o f the subject’s 
eCRF is appropriate  (e.g., ePRO questionnaires ). The source documents should include detailed 
notes on the following:  
• The oral and written communication with the subject regarding the study (including 
the risks and benefits of the study); t he date and time of informed consent(s) must be 
recorded in the source documentation  
• The subject’s medical and disease history before participation in the study  
• The subject’s basic identifying information, such as subject number, that links the 
subject’s s ource documents with the eCRFs  
• The results of all diagnostic tests performed, diagnoses made, therapy provided, and 
any other data on the condition of the subject  
• All TEAEs (All TEAEs may be documented in the source document but only those 
defined in the p rotocol will be transferred to the eCRFs)  
• The subject’s exposure to any concomitant therapy (including start and stop dates, 
route of administration, and dosage)  (All concomitant therapi[INVESTIGATOR_168901])  
ePRO questionnaire data is considered electronic source data created as subjects enter responses 
into the electronic device. Once submitted, responses cannot be changed or m odified by [CONTACT_168987]. There is no source data verification required for such data as is it 
directly attributable to the subject once electronically stored. Therefore, ePRO questionnaire 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   58 results are not transferred to eCRFs.  
12. QUALITY ASSU RANCE AND QUALITY CO NTROL  
This study will be  organized, performed, and reported in compliance with the protocol, SOPs, 
site/Investigator  training , and applicable regulations and guidelines. Clinical Investigator  sites 
will be trained at individual, on-site, Site Initiation Visits. All aspects of the study will be 
monitored carefully by [CONTACT_1034]’s designees with respect to current GCP  and SOPs for 
compliance with applicable government regulations. It is the responsibility of the Investigator  to 
provide al l study records, including CRFs  and source documents, among other records, for 
review and inspection by [CONTACT_24653].  
The Integrated Quality and Risk Management Plan (IQRMP)  details the trial specific quality 
management plans  to indicate how risks are mitigated  and data quality is addressed in the clinical 
trial.  
13. ETHICS/PROTECTION OF  HUMAN SUBJECTS  
13.[ADDRESS_197174]  
The study will be conducted in accordance with the Declaration of Helsinki (1964), including all 
amendments up to and including the Brazil revision (20 13). The Investigator will ensure that this 
study is conducted in full conformity with Regulations for the Protection of Human Subjects of 
Research set forth in US 21 Code of Federal Regulations Part 50, 21 Code of Federal 
Regulations Part 56, and/or the ICH E6.  
13.[ADDRESS_197175]  
The Investigator  agrees to provide the IRB/EC with all appropriate material, including a copy of 
the informed consent form (ICF). The study will not be initiated until the Investigator  obtains 
written  approval of the research plan and the ICF from the appropriate IRB/EC and copi[INVESTIGATOR_168902]. Appropriate reports on the progress of this study 
will be made by [CONTACT_168988]/EC and Sponsor in accordance wit h applicable 
government regulations and in agreement with the policies established by [CONTACT_82170]/EC. Any amendment to the protocol will require review and approval by [CONTACT_168989]. All changes to the consent form will be IRB approved; a 
determination will be made regarding whether previously consented participants need to be re -
consented.  The Sponsor ensures that the IRB/EC complies with the requirements set forth in US 
21 Code of Federal Regulations P art 56.  
13.3 INFORMED CONSENT PRO CESS  
13.3.1  CONSENT/ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED 
TO PARTICIPANT S 
Consent forms describing in detail the study procedures and risks will be given to the potential 
participant and written documentation of informed consent is required prior to starting any 
screening evaluations or other study -related procedures.   
 
Protocol SM04690 -OA-[ADDRESS_197176]’s source record.  
13.4 PARTICIPANT  AND DATA CONFIDENTIALITY  
The Investigator (s) and the Sponsor or its authorized representative w ill preserve the 
confidentiality of all subjects participating in a study, in accordance with GCP, federal, state, and 
local regulations, including, to the extent applicable, the Health Insurance Portability and 
Accountability Act of 1996 (“HIPAA”).  
In ord er to maintain subject confidentiality, all eCRFs, study reports, and communications 
relating to the study will identify subjects by [CONTACT_168990]; subjects 
should not be identified by [CONTACT_2300]. If a subject name [CONTACT_76797] , it must be 
obliterated before a copy of the document is supplied to the Sponsor or its authorized 
representative. Study findings stored on a computer will be stored in accordance with federal, 
state, and local data protection laws. Subjects will be told that representatives of the Sponsor, its 
authorized representative, IRB or EC, or regulatory authorities may inspect their medical records 
to verify the information collected, and that all personal information will be held in strict 
confidence and in accor dance with applicable data protection  laws. The Investigator  will 
maintain a personal subject identification list (subject numbers with the corresponding subject 
names) to make it possible for records to be identified.  
Clinical information will not be rel eased without written permission from the subject, except as 
necessary for monitoring by [CONTACT_1201]/EC, the FDA, or the study Sponsor.  
Any information, inventions, or discoveries (whether patentable or not), innovations, 
suggestions, ideas, and reports made or developed by [CONTACT_737] (s) as a result of conducting 
this study shall be promptly disclosed to the Sponsor and shall be the sole property of the 
Sponsor. The Investigator  agrees, upon the Sponsor’s request and at the Sponsor's expense, to 
execute such documents and to take such other actions, as the Sponsor deems necessary or 
appropriate, to obtain patents in the Sponsor’s name [CONTACT_24668].  
13.4.[ADDRESS_197177] retain copie s of eCRFs (or electronic files), and source 
documents for the maximum period required by (1) applicable regulations and guidelines or 
institution procedures or (2) for the period specified by [CONTACT_1034], whichever is longer. The 
Investigator  must contact  [CONTACT_143250].  
The Sponsor will notify the Investigator  when the study records are no longer needed.  
In the event the Investigator  withdraws from the study (e.g., relocation, retirement), the records 
shall be transferred to a mutually agreed -upon designee (e.g., another Investigator ). Notice of 
such transfer will be given in writing to the Sponsor.  
The Investigator  must ensure that c linical study records are retained according to national 
regulations, as documented in the Clinical Trial Agreement entered into with the Sponsor in 
connection with this study. For example, US federal laws require that an Investigator  maintain all 
study re cords for the indication under investigation for [ADDRESS_197178] be sent t o the site IRB per their guidelines. The site PI/study 
staff is responsible for knowing and adhering to their IRB requirements.   
Refer to the current version of Samumed SOP -300-013 Protocol Deviations  for Sponsor 
procedures related to protocol deviations . 
14.4 PUBLICATION AND DATA  SHARING POLICY  
The Sponsor encourages the scientific publication of data from clinical research studies. 
Investigator s, however, may not present or publish partial or complete study results individually 
without the participation of the  Sponsor. The Investigator (s) and the Sponsor may propose 
appropriate scientific manuscripts or abstracts from the study data. All proposed publications 
must be reviewed and commented on by [CONTACT_128508]. The 
detailed proced ures for the review of publications are set out in the Clinical Trial Agreement 
entered into with the Sponsor in connection with this study. These procedures are in place to 
ensure coordination of study data publication and adequate review of data for publ ication against 
the validated study database for accuracy. Names of all Investigator s and Sponsor representatives 
responsible for designing the study and analyzing the results will be included in the 
publication(s).  
15. STUDY ADMINISTRATION  
15.1 STUDY LEADERSHIP  
The study will be led and conducted by [CONTACT_168935], LLC.  
 
 
 
 
 
 
 
 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   62 16. LITERATURE REFERENCE S  
Altman R. D., Devji T., Bhandari M., Fierlinger A., Niazi F. and Christensen R. (2016). "Clinical 
benefit of intra -articular saline as a comparator in clin ical trials of knee osteoarthritis treatments: 
A systematic review and meta -analysis of randomized trials."  Semin Arthritis Rheum . 46(2): 151 -
159. 
 
Clauw D. J. (2014). "Fibromyalgia: a clinical review."  JAMA . 311(15): 1547 -1555.  
 
Dougados M. and Hochberg M. C. (2011). Management of osteoarthritis. Rheumatology . M. C. 
Hochberg, A. J. Silman, J. S. Smolen, M. E. Weinblatt and M. H. Weisman. PA, [LOCATION_003], Elsevier : 
1793 -1799.  
 
Gelse K., Ekici A. B., Cipa F., Swoboda B., Carl H. D., Olk A.,  Hennig F. F. and Klinger P. 
(2012). "Molecular differentiation between osteophytic and articular cartilage --clues for a 
transient and permanent chondrocyte phenotype."  Osteoarthritis Cartilage . 20(2): 162 -171. 
 
Hochberg M. C., Altman R. D., April K. T., B enkhalti M., Guyatt G., McGowan J., Towheed T., 
Welch V., Wells G., Tugwell P. and American College of R. (2012). "American College of 
Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic 
therapi[INVESTIGATOR_168903], hip, and knee."  Arthritis Care Res (Hoboken) . 64(4): 465 -
474. 
 
Lawrence R. C., Felson D. T., Helmick C. G., Arnold L. M., Choi H., Deyo R. A., Gabriel S., 
Hirsch R., Hochberg M. C., Hunder G. G., Jordan J. M., Katz J. N., Kremers H. M., Wolfe F. 
and Na tional Arthritis Data W. (2008). "Estimates of the prevalence of arthritis and other 
rheumatic conditions in the [LOCATION_002]. Part II."  Arthritis Rheum . 58(1): 26 -35. 
 
Nevitt M. C., Felson D. T. and Lester G. (2006). " A Knee Health Study. " "The Osteoart hritis 
Initiative." . 
 
Saltzman B. M., Leroux T., Meyer M. A., Basques B. A., Chahal J., Bach B. R., Jr., Yanke A. B. 
and Cole B. J. (2016). "The Therapeutic Effect of Intra -articular Normal Saline Injections for 
Knee Osteoarthritis."  Am J Sports Med : [ZIP_CODE] [PHONE_3686].  
 
Ting N., Chen D. -G., Ho S. and Cappelleri J. C. (2017). Phase II Clinical Development of New 
Drugs . Singapore, Springer Singapore.  
 
Wu L., Huang X., Li L., Huang H., Xu R. and Luyten W. (2012). "Insights on biology and 
pathology of HIF -1alpha/ -2alpha, TGFbeta/BMP, Wnt/beta -catenin, and NF -kappaB pathways in 
osteoarthritis."  Curr Pharm Des . 18(22): 3293 -3312.  
 
Zhang W., Robertson J., Jones A. C., Dieppe P. A. and Doherty M. (2008). "The placebo effect 
and its determinants in osteoarthritis: meta -analysis of randomised controlled trials."  Ann Rheum 
Dis. 67(12): 1716 -1723.  
 
 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   63 APPENDIX  
Appendix 1.  Guidance for Industry: Toxicity Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Trials   
Table A1: Tables for Clinical Abnormalities  
Local Reaction to  
Injectable Product  Mild (Grade 1)  Moderate (Grade 
2)  Severe (Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Pain  Does not interfere  
with activity  Repeated use of 
non-narcotic pain 
reliever > 24 hours 
or interferes with 
activity  Any use of narcotic 
pain reliever or 
prevents daily  
activity  Emergency room  
(ER) visit or  
hospi[INVESTIGATOR_168904]/Redness *  2.5 – 5 cm  5.1 – 10 cm  > 10 cm  Necrosis or 
exfoliative dermatitis  
Induration/Swelling 
**  2.5 – 5 cm and does 
not interfere  
with activity  5.1 – 10 cm or  
interferes with  
activity  > 10 cm or  
prevents daily  
activity  Necrosis  
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be 
recorded as a continuous variable.  
** Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement.  
Vital Signs *  Mild (Grade 1)  Moderate (Grade 
2)  Severe (Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Fever (°C) **  
(°F) **  38.0 – 38.4  
100.4 – 101.1  38.5 – 38.9  
101.2 – 102.0  39.0 – 40  
102.1 – 104  > 40  
> 104  
Tachycardia - beats 
per minute  101 – 115  116 – 130  > 130  ER visit or  
hospi[INVESTIGATOR_168905] - beats 
per minute***  50 – 54  45 – 49  < 45  ER visit or  
hospi[INVESTIGATOR_168906] 
(systolic) - mm Hg  141 – 150  151 – 155  > 155  ER visit or 
hospi[INVESTIGATOR_168907] 
(diastolic) - mm Hg  91 – 95  96 – 100  > 100  ER visit or  
hospi[INVESTIGATOR_168908] 
(systolic) - mm Hg  85 – 89  80 – 84  < 80  ER visit or  
hospi[INVESTIGATOR_168909] – 
breaths per minute  17 – 20  21 – 25  > 25  Intubation  
* Subject should be at rest for all vital sign measurements.  
** Oral temperature; no recent hot or cold beverages or smoking.  
*** When resting heart rate is between 60 – [ADDRESS_197179] populations, for example, conditioned athletes.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   64 Systemic (General)  Mild (Grade 1)  Moderate (Grade 
2)  Severe (Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Nausea/vomiting  No interference  
with activity or 1 – 
2 
epi[INVESTIGATOR_1841]/24 hours   Some interference  
with activity or > 2  
epi[INVESTIGATOR_1841]/24 hours  Prevents daily 
activity, requires 
outpatient IV 
hydration  ER visit or  
hospi[INVESTIGATOR_168910]  2 – 3 loose stools or  
< 400 gms/24 hours  4 – 5 stools or  
400 – 800 gms/24  
hours  6 or more watery  
stools or >800gms 
/24 hours or 
requires  
outpatient IV  
hydration  ER visit or  
hospi[INVESTIGATOR_168911]-  
narcotic pain 
reliever > 24 hours 
or some interference  
with activity  Significant; any  
use of narcotic  
pain reliever or  
prevents daily  
activity  ER visit or  
hospi[INVESTIGATOR_168912]; 
prevents daily 
activity  ER visit or  
hospi[INVESTIGATOR_168913]; 
prevents daily 
activity  ER visit or  
hospi[INVESTIGATOR_168914] (Grade 1)  Moderate (Grade 
2) Severe (Grade 3)  Potentially Life 
Threatening 
(Grade 4)  
Illness or clinical 
adverse event (as 
defined according to 
applicable 
regulations)   No interference 
with activity   Some interference 
with activity not 
requiring medical 
intervention  Prevent s daily 
activity and requires 
medical intervention  ER visit or 
hospi[INVESTIGATOR_168915]04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   65 Table A2:  Tables for Laboratory Abnormalities  
Serum *  Mild (Grade 1)  Moderate 
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening (Grade 
4)**  
Sodium – Hyponatremia 
mEq/L  132 – 134  130 – 131  125 – 129  < 125  
Sodium – Hypernatremia 
mEq/L  144 – 145  146 – 147  148 – 150  > 150  
Potassium – Hyperkalemia 
mEq/L  5.1 – 5.2  5.3 – 5.4  5.5 – 5.6  > 5.6  
Potassium – Hypokalemia 
mEq/L  3.5 – 3.6  3.3 – 3.4  3.1 – 3.2  < 3.1  
Glucose – Hypoglycemia 
mg/dL  65 – 69  55 – 64  45 – 54  < 45  
Glucose – Hyperglycemia  
Fasting – mg/dL  
Random – mg/dL  100 – 110  
110 – 125  111 – 125  
126 – 200  >125  
>200  Insulin requirements or 
hyperosmolar coma  
Blood Urea Nitrogen  
BUN mg/dL  23 – 26  27 – 31  > 31  Requires dialysis  
Creatinine – mg/dL  1.5 – 1.7  1.8 – 2.0  2.1 – 2.5  > 2.5 or requires dialysis  
Calcium – hypocalcemia 
mg/dL  8.0 – 8.4  7.5 – 7.9  7.0 – 7.4  < 7.0  
Calcium – hypercalcemia 
mg/dL  10.5 – 11.0  11.1 – 11.5  11.6 – 12.0  > 12.0  
Magnesium – 
hypomagnesemia mg/dL  1.3 – 1.5  1.1 – 1.2  0.9 – 1.0  < 0.9  
Phosphorous – 
hypophosphatemia mg/dL  2.3 – 2.5  2.0 – 2.2  1.6 – 1.9  < 1.6  
CPK – mg/dL  1.25 – 1.[ADDRESS_197180]***  1.6 – 3.[ADDRESS_197181]  3.1 –[ADDRESS_197182]  > [ADDRESS_197183]  
Albumin – Hypoalbuminemia 
g/dL  2.8 – 3.1  2.5 – 2.7  < 2.5  --  
Total Protein – 
Hypoproteinemia g/dL  5.5 – 6.0  5.0 – 5.4  < 5.0  --  
Alkaline phosphate –  
increase by [CONTACT_12245]  1.1 – 2.[ADDRESS_197184]  2.1 – 3.[ADDRESS_197185]  3.1 – [ADDRESS_197186]  > [ADDRESS_197187]  
Liver Function Tests –ALT, 
AST  
increase by [CONTACT_12245]  1.1 – 2.[ADDRESS_197188]  2.6 – 5.[ADDRESS_197189]  5.1 – [ADDRESS_197190]  > [ADDRESS_197191]  
Bilirubin – when accompanied  
by [CONTACT_168991]  1.1 – 1.[ADDRESS_197192]  1.26 – 1.[ADDRESS_197193]  1.51 – 1.[ADDRESS_197194]  > 1.[ADDRESS_197195]  
Bilirubin – when Liver 
Function Test is normal; 
increase by [CONTACT_12245]  1.1 – 1.[ADDRESS_197196]  1.6 – 2.[ADDRESS_197197]  2.0 – 3.[ADDRESS_197198]  > 3.[ADDRESS_197199]  
Cholesterol  201 – 210  211 – 225  > 226  ---  
Pancreatic enzymes – amylase, 
lipase  1.1 – 1.[ADDRESS_197200]  1.6 – 2.[ADDRESS_197201]  2.1 – 5.[ADDRESS_197202]  > 5.[ADDRESS_197203]  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   66 ** The clinical signs or symptoms a ssociated with laboratory abnormalities might result in characterization of the 
laboratory abnormalities as Potentially Life Threatening (Grade 4). For example, a low sodium value that falls 
within a grade 3 parameter (125 -129 mE/L) should be recorded as a  grade [ADDRESS_197204] 
had a new seizure associated with the low sodium value.  
*** “ULN” is the upper limit of the normal range.  
Hematology *  Mild (Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening (Grade 
4)  
Hemoglobin (Female) - gm/dL  11.0 – 12.0  9.5 – 10.9  8.0 – 9.4  < 8.0  
Hemoglobin (Female)  
change from baseline value - 
gm/dL  Any decrease – 
1.5  1.6 – 2.0  2.1 – 5.0  > 5.0  
Hemoglobin (Male) - gm/dL  12.5 – 13.5  10.5 – 12.4  8.5 – 10.4  < 8.5  
Hemoglobin (Male)  
change from baseline value – 
gm/dL  Any decrease – 
1.5  1.6 – 2.0  2.1 – 5.0  > 5.0  
WBC Increase - cell/mm3 10,800 – 15,000  15,001 – 
20,000  20,001 –        
25, 000  > 25,000  
WBC Decrease - cell/mm3 2,500 – 3,500  1,500 – 2,499  1,000 – 1,499  < 1,000  
Lymphocytes Decrease - cell/mm3 750 – 1,000  500 – 749  250 – 499  < 250  
Neutrophils Decrease - cell/mm3 1,500 – 2,000  1,000 – 1,499  500 – 999  < 500  
Eosinophils - cell/mm3 650 – 1500  1501 - 5000  > 5000  Hypereosinophilic  
Platelets Decreased - cell/mm3 125,000 – 
140,000  100,000 – 
124,000  25,000 – 
99,000  < 25,000  
PT – increase by [CONTACT_12245]  
(prothrombin time)  1.0 – 1.[ADDRESS_197205]**  1.11 – 1.[ADDRESS_197206]  1.21 – 1.[ADDRESS_197207]  > 1.[ADDRESS_197208]  
PTT – increase by [CONTACT_12245]  
(partial thromboplastin time)  1.0 – 1.[ADDRESS_197209]  1.21 – 1.[ADDRESS_197210]  1.41 – 1.[ADDRESS_197211]  > 1.[ADDRESS_197212]  
Fibrinogen increase - mg/dL  400 – 500  501 – 600  > 600  --  
Fibrinogen decrease - mg/dL  150 – 200  125 – 149  100 – 124  < 100 or associated  
with gross bleeding  
or disseminated 
intravascular 
coagulation (DIC)  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
** “ULN” is the upper limit of the normal range.  
 
Urine *  Mild (Grade 1)  Moderate  
(Grade 2)  Severe (Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Protein  Trace  1+  2+  Hospi[INVESTIGATOR_168916]  1+  2+  Hospi[INVESTIGATOR_168917] (microscopic) – 
red blood cells per high 
power field (rbc/hpf)  1 - 10  11 – 50  > 50 and/or gross 
blood  Hospi[INVESTIGATOR_168918] 
(PRBC) transfusion  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   67 Appendix 2.  Prohibited Concomitant Medications and Procedures (Supplement)  
 
Excluded and prohibited centrally acting analgesics include, but are not limited to, the following:  
Gabapentin (Neurontin, Horizant, Gaberone, Gralise, F usepaq Fanatrex)  
Pregabalin (Lyrica)  
Carbamazepi[INVESTIGATOR_050] (Tegretol, Carbatrol, Epi[INVESTIGATOR_29106], Equetrol)  
Duloxetine (Cymbalta, Irenka)  
Milnacipran (Savella)  
Tramadol (Ultram, Ryzolt, Conzip, Rybix ODT, Fusepaq Synapryn)  
Tapentadol (Nucynta)  
Orphenadrine Citrate (Norflex , Orfro, Orphenate, Mio -Rel, Antiflex)  
Amitriptyline (Elavil, Vanatrip)  
Clomipramine ( Anafranil)  
Nortriptyline (Aventyl, Pamelor)  
Desipramine (Norpramin)  
Imipramine (Tofranil)  
Doxepin (Prudoxin, Sinequan, Zonalon, Silenor)  
Ketamine (Ketalar)  
Sodium Oxybate  (Xyrem, GHB)  
Other non -listed anticonvulsants are also prohibited while use for seizure prophylaxis or 
migraine prophylaxis would be permitted.  
 
Excluded and prohibited electrotherapy treatments include, but are not limited to, the following:  
Diathermy  
TENS  
NMES  
Interferential therapy  
Shortwave therapy  
Iontophoresis  
LASER  
Ultrasound  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   68 Appendix 3.  Amendments  
 
AMENDMENT 03 VERSION 00 SUMMARY OF CHANGES  
Study Title:  A Phase 2, 24 -Week, Multicenter, Randomized, Double -Blind, 
Placebo -Controlled Study Evaluating the Safety and Efficacy of 
SM04690 for the Treatment of Moderately to Severely Symptomatic 
Knee Osteoarthritis   
Purpose:  The primary purpose of this amendment is to refine and clarify the 
analytical  design . Additional administrative changes and corrections 
are also made.  
Summary of Changes:  The table below provides a list of changes and their rationale  
Change  Sections Affected  Rationale  
“Amendment 0 3 Version 00 ” and 
updated date have been added on the title 
page.  Title Page  Change was made to capture the dates 
of all previous and current protocol 
versions  
Protocol date and version have been 
updated as applicable.  All Change was made to reflect current 
protocol amendment  
Titles have been updated for Christopher 
Swearingen and Ismail Simsek.  Sponsor Signature [CONTACT_169000] [ADDRESS_197213] of Abbreviati ons Change was made to capture additions 
and removal of various abbreviations 
in this amendment.  
The following was added as a Secondary 
Endpoint: “ Evaluate change from 
baseline OA disease activity as assessed 
by [CONTACT_168927] 
24” Protocol Summary , 
Section 4.2.2 , and  Section 
10.4.3  Change was made to refine study 
outcomes in alignment with regulatory 
labeling requirements . 
The following was added as an 
Exploratory Endpoint: “ Evaluate 
outcome differences between treatment 
with sham or placebo injections at Week 
4, 8, 12, 16, 20, and 24” Protocol Summary , 
Section 4.2.[ADDRESS_197214] the investigational rationale for 
including the sham procedure . 
A correction was made in the Primary 
Endpoints section. #4 erroneously said 
“Week 2” instead of “Week 24”.  Section 4.2.[ADDRESS_197215] an error 
and align with the Protocol Summary  
A correction was made to Section 7.1.1 
which incorrectly noted the WOMAC 
version as “N R3.1”. This was corrected 
to “NRS 3.1”.  Section 7.1.[ADDRESS_197216] an error  
The following edit was made in Section 
8.3: “TEAEs that are not serious and are 
ongoing at the subject’s last visit will be 
followed for a maximum of 30 days  until 
the study close -out visit, if requested .” Section 8.[ADDRESS_197217] the in vestigational rationale for 
stratifying by [CONTACT_168992].  
 
  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   70 AMENDMENT 02 VERSION 00 SUMMARY OF CHANGES  
Study Title:  A Phase 2, 24 -Week, Multicenter, Randomized, Double -Blind, 
Placebo -Controlled Study Evaluating the Safety and Efficacy of 
SM04690 for the Treatment of Moderately to Severely Symptomatic 
Knee Osteoarthritis   
Purpose:  The purpose of this amendment is to refine and clarify the study design  
Summary of Changes:  The table below provides a list of changes and their rationale  
Change  Sections Affected  Rationale  
“Amendment 0 2 Version 00 ” and 
updated date have been added on the title 
page.  Title Page  Change was made to capture the dates 
of all previous and current protocol 
versions  
Protocol date and version have been 
updated as applicable.  All Change was made to reflect current 
protocol amendment  
The screening window was changed from 
[ADDRESS_197218] occur between 
Days  -12 and -7. Protocol Summary, 
Section 4.1, Section 7.3.1 , 
and Section 7.3.6   Change was made to refine study 
design; baseline questionnaires can be 
completed up to 7 days prior to Day 1  
Approximate number of subjects to be 
enrolled was updated from 330 to 630.  Protocol Summary, 
Schematic of Study 
Design, Section 4.1, and  
Section 10.5 Change was made to refine study 
design; s ample size is being incr eased 
in accord with current dose -finding 
statistical practice  
Subjects will complete a daily  electronic 
diary of NSAID usage  generally, not just 
for the treatment of OA pain.  Protocol Summary, 
Section 4.1, Section 4.2.3 , 
Section 7.1.1 , Section 
10.4.4 , and Section 10.4.7  Change was made to refine study 
design; subjects will document any 
NSAID usage  
Edits were made to Exclusion Criterion 
#6 for clarification; “regular use” applies 
only to ambulatory assistive devices and 
“structural knee braces” are braces that 
contain ha rdware.  Protocol Summary and 
Section 5.2 Change was made to clarify the 
exclusion criterion  
“Corticosteroids” was replaced with 
“glucocorticoids” throughout the 
protocol.  Protocol Summary, 
Section 5.2, and Section 
7.6 Change was made for clarity and 
correctness; not all corticosteroids are 
excluded (e.g., mineralocorticoids are 
allowed), but all glucocorticoids are 
excluded  
Study duration and estimated date of last 
subject complection  were updated.  Protocol Summary  Change was made for accuracy  
Risks and symptoms associated with 
serious allergic reactions were added to 
Section 2.3.1.  Section 2.3.1  Change was made to align with the 
Informed Consent Form  
The following edits were made:  
-Deleted, “Re -screens are limited to 
subjects who did not meet 
inclusion/exclusion criteria at Screening 
Visit 1  due to a transient reason.”  
-Added, “ Diary non-compliance is not a Section 4.1 Change was made to refine study 
design; re -screens are allowed if 
subjects screen fail due to transient 
reasons at Screening Visit 2 or Day 1  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   71 Change  Sections Affected  Rationale  
transient event and subjects with diary 
non-compliance may not be re -screened .” 
Additional reasons for withdrawal or 
early termination were added:  
•Request by [CONTACT_168950]  
•Study terminated by [CONTACT_168993] 5.5.1  Change was made for completeness  
The following was added in Section 
6.1.5: “… if it is the standard practice of 
the Investigator, a small amount (0.3 -0.5 
mL) of joint fluid can be aspi[INVESTIGATOR_3831] (if 
present) in order to confirm correct 
needle placement; the aspi[INVESTIGATOR_168919] -injected. ” Section 6.1.5  Change was made to clarify the 
procedure  
The following addition was made in 
Section 6.2: “ Quantity returned /used  
(active vial, vehicle vial) ” Section 6.2 Change was made to clarify the study 
drug accountability procedures  
The following addition was made in 
Section 6.2: “Procedures for Investigator 
return or destruction  of used and unused 
vials of the study medication and vehicle 
will be provided in the Pharmacy 
Manual.”  Section 6.2 Change was made for completeness as 
some sites may destroy used and 
unused vials of medication   
The following edit was made in the 
Collection of Adverse Events Data 
section: “ The subject  will may be asked 
to return to the site  for an unscheduled 
visit if a TE AE occurs between study 
visits …” Section 7.1.1  Change was made for correctness  
The etiology of all TEAEs will be 
recorded in the eCRF.  Section 7.1.1  Change was made to refine study 
design  
The following edit was made in the 
Collection of Adverse Events Data 
section: “ TEAEs  that are not serious and 
are ongoing at the subject’s last visit w ill 
be followed for a maximum of 30 days  
until the study site close -out visit, if 
requested .” Section 7.1.1  Change was made to refine study 
design; non -serious TEAEs may be 
followed until the study site close -out 
visit 
The following was added to the Day 1 
Visit description: “S ubjects with a  period  
of more than 12 days between Screening 
Visit 2 and Day 1 are to be screen failed 
due to the lengthened time between 
baseline questionnaires and study 
medication injection.”  Section 7.3.2  Change was made to emphasize the 
importance of the screening visit 
windows  
The followi ng edit was made to Section 
10.5: " The sample size for this study was 
based upon accepted dose finding  
statistical practice  (Ting 2017) .” Section 10.5, Section [ADDRESS_197219] an error  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   72 Change  Sections Affected  Rationale  
Summary of Changes: “ other cosmetic 
injections are also prohibited allowed 
during the study ” 
 
  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   73  
AMENDMENT 01 VERSION 00 SUMMARY OF CHANGES  
Study Title:  A Phase 2, 24 -Week, Multicenter, Randomized, Double -Blind, 
Placebo -Controlled Study Evaluating the Safety and Efficacy of 
SM04690 for the Treatment of Moderately to Severely Symptomatic 
Knee Osteoarthritis   
Purpose:  The purpose of this amendment is to refine and clarify the study design  
partially in response to site and IRB feedback  
Summary of Changes:  The table below provides a list of changes and their rationale  
Change  Sections Affected  Rationale  
“Amendment 01 Version 00” and 
“Original Protocol Date” have been 
added on the title page.  Title Page  Change was made to capture the dates 
of all previous and current protocol 
versions  
Protocol date and version have been  
updated as applicable.  All Change was made to reflect current 
protocol amendment  
Additional terms were added to the List 
of Abbreviations.  List of Abbreviations  Change was made for completeness ; 
new abbreviations were used in the 
amendment   
Primary an d secondary objectives were 
revised.  Summary and Section 3 Change was made to better clarify 
primary and secondary objectives  
The timepoint of the pain NRS primary  
enpoint was revised to Week 24 instead 
of Week 12.  Evaluation of change from 
baseline OA pain and OA function at 
Week 24 and in medial JSW at Week 24 
were added as primary endpoints.  
Analysis of primary endpoints in the 
Statistical Considerations section was 
revised accordingly .  Summary , Section 4.2.1 , 
and Section 10.4.2  Change was made to further refine 
study endpoints  
Secondary endpoints were nar rowed 
down to evaluation of safety of SM04690 
as measured by [CONTACT_38915] . Analysis of 
secondary endpoints  in the Statistical 
Considerations section  was revised 
accordingly.  Summary , Section  4.2.2 , 
and Section 10.4.3  Change was made to further refine 
study endpoints  
Remaining secondary endpoints were 
added to exploratory endpoints . 
Exploratory analyses  in the Statistical 
Considerations section  were revis ed 
accordingly.  Summary, Section 4.2.3 , 
and Section 10.4.7  Change was made to further refine 
study endpoints  
“Evaluate subject perception of study 
treatment received at Week 24” was 
added as an exploratory objective. 
Exploratory analyses in the Statistical 
Considerations section were revised 
accordingly.  Summary, Section 4.2.3 , 
and Section 10.4.7  Change was made to further refine 
study endpoin ts 
“Monthly” and “weekly” descriptors Summary, Section 4.2.2 , Change was made to further refine 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   74 Change  Sections Affected  Rationale  
were removed from study endpoints.  and Section 4.2.3  study endpoints  
The screening period was increased from 
14 days to 21 days. Participant duration 
was changed to “Up to approximately 
2627 weeks.” Screening Visit windows 
were added.  Summary, Section 4.1, 
Section 7.3.1 , Section 
7.3.2 , and Section 7.3.6  Change was made per site feedback to 
allow a larger screening window  
The interim analysis has been removed 
from the study.  Summary, Section 4.1, 
Section 10 Change was made to align with 
updated study endpoints; an interim 
analysis is no longer necessary  
The fo llowing was deleted from inclusion 
criterion #2: “(single assistive devices 
such as canes allowed if needed less than 
50% of the time)  Summary and Section 5.1 Change was made to refine inclusion 
criteria; information regarding 
assistive devices was added to 
exclusion criterion #6  
The following was added to inclusion 
criterion #5: “Primary source of pain 
throughout the body is  due to OA in the 
target knee.”  Summary and Section 5.[ADDRESS_197220] in the knee, should be 
due to OA in the target knee  
Inclusion criterion #10 was revised: Total 
WOMAC score of 96 -192 (out of 240) 
for the target knee at baseline  regardless 
of if the subject is on symptomatic oral 
treatment ( baseline questionnaire 
completed  during the screening period 
prior to randomization)  Summary and Section 5.1 Change was made for consistency with 
terminology; baseline WOMAC 
scores, which will be assessed during 
the screening period, will be used for 
eligibility  
Inclusion criterion #12 was revised. 
Amphetamines were deleted. Prohibited 
concomitant medications were revi sed 
accordingly.  Summary, Section 5.1, and 
Section 7.6  Change was made for accuracy; 
subjects must test negative for 
meth amphetamines and are prohibited 
from using meth amphetamines while 
on the study; methamphetamines are 
already covered under “ drugs of 
abuse”  
Inculsion criterion #16 was revised to 
“Subject’s Day [ADDRESS_197221] occur while…”  Summary and Section 5.1 Change was made as subjects who are 
screened before the cohort closes will 
still be allowed to enroll if all other 
eligibiligy criteria are met  
Exclusion criterion #6 was revised: 
“Currently  requires regular use of 
ambulatory assistive devices (e.g., 
wheelchair, parallel bars, walker, canes, 
or crutches) or  use of a walker,  lower 
extremity prosthesis, and/or a structural 
patellofemoral  knee brace ” Summary and Section 5.2 Change was made to refine exclusion 
criteria; regular use of ambulatory 
assistive devices is excluded  
The timing of exclusion criteria #9, 1 8 
(previously 19), 1 9 (previously 20 ), 22 
(previously 23), and 23  (previously 24 ) 
were revised to “ Screening Visit 1.”  Summary and Section 5.2 Change was made for consistency with 
other exclusion criteria  
“Gout or pseudogout” was added to 
exclusion criterion #15 and exclusion 
criterion #16 was deleted.  Summary and Section 5.2 Change was made to refine exclusion 
criteria; gout or pseudogout are 
excluded altogether  
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   75 Change  Sections Affected  Rationale  
Exclusion criterion #18 (previously 19) 
was revised. Participation in an 
observational research trial  related to 
osteoarthritis  or plan ned participation in 
clinical research trials are excluded. The 
prohibited medications, treatments, and 
procedures section was updated 
accordingly.  Summary, Section 5.2, and 
Section 7.6 Change was made to refine exclusion 
criteria and prohibited medications, 
treatments, and therapi[INVESTIGATOR_014]; participation 
in the noted clinical trials is excluded 
and prohibited  
“Glucocorticosteroid s”, “corticosteroids”, 
and “glucocorticoids” were revised to 
only “corticosteroids.”  Summary, Section 5.2, and 
Section 7.6 Change was made for consistency and 
simplicity  
New exclusion criterion #20 was added: 
Any intra -articular injection into the 
target knee with a therapeutic aim 
including but not limited to 
viscosupplementation (e.g., hyaluronic 
acid), PRP, and stem cell therapi[INVESTIGATOR_6523] 
24 weeks prior to Screening Visit 1 ; 
treatment of the target knee with intra -
articular corticosteroids greater than 12 
weeks prior to Screening Visit 1 is 
allowed .  
-Exclusio n criterion #22 regarding 
viscosupplementation was deleted as it 
was merged with the new #20.  
-The prohibited medications, treatments, 
and procedures section was updated 
accordingly.  Summary, Section 5.2, and 
Section 7.6 Change was made to refine exclusion 
criteria; any IA injection into the target 
knee with therapeutic intent is 
excluded  
Exclusion criterion #21 was revised from 
“equivalent to 10 mg prednisone or 
more” to “greater than 10 mg prednisone 
or the equivalent…” The prohibited 
medications, treatments, and procedures 
section was updated accor dingly.  Summary, Section 5.2, and 
Section 7.6 Change was made to refi ne exclusion 
criteria and prohibited medications; 
greater than 10 mg prednisone or the 
equivalent is excluded and prohibited  
Exclusion criterion #25 (previously 26) 
was revised to: “ Subjects requiring the 
chronic use (i.e., regular use for ≥ 12 
weeks)  Use of centrally acting analgesics 
(e.g. duloxetine)  (refer to Appendix 2 ) 
within 12 weeks prior to Screening Visit 
1.” The prohibited medications, 
treatments, and procedures section and 
Appendix 2 was updated accordingly.  Summary, Section 5.2, 
Section 7.6, and Appendix 
2 Change was made to refine the 
exclusion criterion; any use of 
centrally acting analgesics within 12 
weeks of Screening Visit 1 is 
excluded/prohibited  
New exclusion criterion #26 was added: 
“Use of anticonvulsants not listed in 
Appendix 2  within 12 weeks prior to 
Screening Visit 1, unless used for seizure 
or migraine prophylaxis”  Summar y, Section 5.2, 
Section 7.6, and Appendix 
2 Change was made to refine the 
exclusion criterion; any use of 
anticonvulsants not l isted in Appendix 
2 is excluded/prohibited, unless used 
for seizure or migraine prophylaxis  
Definition of chronic use in exclusion 
criterion #27 was changed from “ regular 
use for ≥ 12 weeks” to “ usage > 1 x per Summary and Section 5.2 Change was made to clarify the 
definition of chronic opi[INVESTIGATOR_168920]04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   76 Change  Sections Affected  Rationale  
week .” 
New exclusion criterion #30 was added:  
If on NSAIDs for the treatment of OA 
pain, subjects who have not maintained a 
stable regimen in the opi[INVESTIGATOR_168921] 1.  Summary and Section 5.2 Change was made to refine exclusion 
criteria; subjects should be on a stable 
regimen of NSAIDs (if using them for 
OA pain) prior to the study  
Exclusion criterion #32 (previously 31) 
was revi sed to state “… any investigative 
site…”  Summary and Section 5.2 Change was made to refine exclusion 
criteria; subjects who are directly 
affiliated or are immediate  family 
members of personnel directly 
affiliated with the study at any 
investigative site are excluded  
Exclusion criterion #33 (previously 32) 
was revised to add immediate family 
members.  Summary and Section 5.2 Change was made to refine exclusion 
criteria; subjects employed by 
[CONTACT_168994] [ADDRESS_197222] of 
the IRB  
Additional information regarding 
possible risks associated with study 
vehicle were added to Section 2.3.1 
(Study Medicat ion SM04690).  Section 2.3.1  Change was made for completeness; 
there are some risks associated with 
study vehicle  
Edits were made to the interim analysis 
description in Section 2.3.1 (Study 
Medication SM04690 ). Section 2.3.1  Change was made for accuracy; the 
OA-02 safety summary provided is per 
the interim analysis data  (not a locked 
database). Extra information was 
deleted for c onsistency with the IB  
Known potential risks related to the study 
placebos were added to Section 2.3.1.  Section 2.3.1  Change was made for completeness; 
there are some risks associated with 
placebo injections  
The following was added to Section 4.1: 
“To support the primary objective, active 
treatment groups w ill be compared to 
both vehicle (2.0 mL vehicle) and sham 
(0.0 mL vehicle).”  Section 4.1 Change was made to clarify study 
design  
“Seasonal allergies ” was deleted from 
examples of transient reasons for screen 
failure.  Section 4.1 Change was made because seasonal 
allergies was not a good example of a 
transient re ason 
Details regarding the evaluation of the 
success of blinding were added to the Section 4.1, Section 7.1.1 , 
Section 7.3.4 , Section Change was made for completeness; 
the evaluation was previously 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   77 Change  Sections Affected  Rationale  
protocol.  7.3.5 , and Section 7.3.6 , 
and Section 10.4.7  mentioned in Section 10.6.2 without 
further details  
The following was added to Section 
6.1.5: “Although not required, the 
injection may be guided by [CONTACT_168995].”  Section 6.1.[ADDRESS_197223]; 
clarification regarding ultrasound 
guidance was needed  
Information regarding how to perform the 
intra-articular injections (active vs. 
vehicle vs. sham) was added to Section 
6.1.5.  Section 6.1.[ADDRESS_197224] of 
the IRB  
The following deletion was made in 
Section 6.2: “ All study medication and 
vehicle received,  prepared, and 
dispensed…”  Section 6.2 Chang e was made for accuracy; study 
medication and vehicle may be 
received by [CONTACT_168996].  
Widespread Pain Index and Symptom 
Severity Form terminology was updated 
throughout.  Sections 4.1, 7.1.1 , 7.3.1 , , 
7.3.6 , 10.4.8 , and 10.6.1  Changes were made for consistency 
with Sponsor terminology  
The WPI&SS assessment will be 
performed at Screening Visit 1 instead of 
Screening Visit 2.  Sections 4.1, 7.1.1 , 7.3.1 , 
and 7.3.6  Change was made to aid with 
stratification of cohorts  
The following was deleted from the Knee 
Examination description: “ Presence of 
significant misalignment in either knee 
(yes/no) will be recorded in the eCRF.”  Section 7.1.1  Change was made because this 
information will not be recorded in the 
eCRF ; this information would be 
captured via exclusion criterion #11  
The Vital Signs description was revised: 
“Blood pressure (systolic and diastolic) 
after the subject sitsrests (sitting or 
supi[INVESTIGATOR_050])  for at least 5  minutes ; same 
resting position should be used for all 
blood pressure measurements throughout 
the study”  Section 7.1.[ADDRESS_197225] in either sitting or supi[INVESTIGATOR_168922]&SS, the following 
deletions were made: “ Upon completion 
of the WPI&SS assessment, both the 
subject and the study staff member  will 
sign/initial and date…”  Section 7.1.1  Change was made because study staff 
are not required to sign the WPI&SS 
form  
Additional detail regarding data storage 
was added to the Electronic Diary Devi ce 
Provision and Training section.  Section 7.1.1  Change was made to inform sites of 
the duration of data storage to ensure 
data and reports are reviewed in a 
timely manner  
The Pain Numeric Rating Scale (NRS) 
description was modified to indicate that 
the subject would be reporting “ average 
knee pain in the last 24 hours.”  Section 7.1.1  Change was made to clarify the pain 
NRS assessment  
The description of “just prior to going to 
bed” was removed throughout the 
protocol.  Sections 7.1.1 , 7.3.1 , 7.3.2 , 
and 7.3.7  Change was made to avoid confusion; 
bedtimes may vary so subjects are just 
required to complete the 
questionnaires between 5 pm and 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   78 Change  Sections Affected  Rationale  
11:59 pm  
The description of “from home” was 
replaced with “remotely on their 
electronic devices” throughout the 
protocol.  Sections 7.1.1 , 7.3.1 , 7.3.2 , 
and 7.3.7  Change was made to avoid confusion; 
questionnaires need only be performed 
remotely  
Definitions of non -compliance (missing 
greater than 3 of 7 entries in a given 
week) were added to the pain NRS and 
NSAIDs electronic diary descriptions.  Secti on 7.1.[ADDRESS_197226] to 
clarify the definition of non -
compliance and subsequent courses of 
action  
The timeframe to complete baseline 
questionnaires was updated to Screening 
Visit 2 + 5 days (or up until the day 
before the Day 1 visit).  Sections 7.1.[ADDRESS_197227] to 
allow for a larger window  to complete 
baseline questionnaires  
The Patient Global Assessment 
description was changed from 100 mm 
VAS to 50 mm VAS.  Section 7.1.1  Change was made for accuracy; the 
Patient Global Assessment is a 50 mm 
VAS  
It was clarified that the  WPI&SS 
assessment and the Physician Global 
Assessment will be performed on paper.  Section 7.1.1  Change was made for clarity; these 
assessments will not be performed on 
the electronic device  
Section 7.2.1 was revised to state, “ Urine 
microscopy will be performed if 
urinalysis urine protein, leukocyte 
esterase (WBC esterase ), occult blood, or 
nitrites values are out of range or if the 
investigator deems that the microscopy is 
clinically warranted .”  Section 7.2.1  Change was made per site feedback  
Section 7.2.1 was revised to state: “ The 
subject must not be randomized on Day 1 
and, if results are available for review 
prior to Screening Visit 2 , is not 
recom mended to be scheduled for  
proceed to Screening Visit 2…”  Section 7.2.1  Change was made for clarity; if 
laboratory results are available, it is 
recommended that they are reviewed 
prior to the Screening 2 visit  
“MDMA” was replaced with “ecstasy” in 
the urine dru g test panel.  Section 7.2.[ADDRESS_197228] description  
ACM Global Central Laboratory was 
changed to ACM Global Laboratory.  Section 7.2.3  and Section 
7.2.4  Change was made to align with the 
labor atory’s name [CONTACT_48599].  
The following was added to Screening 
Visit 1: “ In order to complete 
randomization, WPI&SS scores and 
subject bilateral/unilateral status from 
Screening Visit [ADDRESS_197229] be entered into 
EDC prior to the study reaching the 
enrollment caps d escribed in Section 
7.3.2 .” Section 7.3.1   Change was made to remind sites to 
enter WPI&SS scores and subject 
bilateral/unilateral status into the EDC 
after Screen ing Visit 1  
The screening window was increased to 
21 days: SV1 (Day -21 to -10) and SV2 
Day -11 to Day -7). Section 7.3.[ADDRESS_197230] to 
allow a larger screening window  
Section 7.3.2 was renamed Section  7.3.2   Change was made for accuracy; the 
Day 1 visit neither qualified as the 
Protocol SM04690 -OA-04  
Samumed, LLC  AM0 3V00 
23 April  2018 
 
Confidential   79 Change  Sections Affected  Rationale  
“Randomization”.  consent or baseline visit (some 
baseline assessments are to be 
performed prior to Day 1)  
Information regarding randomization 
cohorts and eligibility for randomization 
was added to the Day 1 visit.  Section 7.3.2  Change was made for clarity; 
randomizatio n cohorts were previously 
mentioned without a description  
In Section 7.3.2, “ with a window of -2 
days” was deleted from the description of 
monthly and weekly assessments.  Section 7.3.2  Change was made to avoid confusion; 
details on questionnaire completion 
are provided in Section 7.3.7  
“Return of electronic device” was added 
to the EOS and ET visits.  The study 
procedures d escription and schedule of 
events table were revised accordingly.  Section 7.1.1 , Section 
7.3.4 , Section 7.3.5 , and 
Section 7.3.6  Change was made for completeness; 
subjects are to return their devices at 
the EOS or ET visit  
The following sentence s were deleted 
from Section 7.6: “ Subjects will be 
encouraged to remain on a stable dose of 
any allowed medications throughout the 
study. The use of aspi[INVESTIGATOR_248] (325 mg/day) 
for thrombosis prophylaxis is permitted.”  Section 7.6 Change was made to avoid confusion; 
NSAIDs are allowed on this study  
The first bullet point of the prohibited 
concomitant medications and procedures 
list was revised to cover any intra-
articular i njection into either knee.  Section 7.6 Change was made for clarification; 
any intra -articular injections into either 
knee are prohibited during the study  
New formalized (i.e., prescribed by a 
medical professional) exercise physical 
therapy exercise programs for knee OA 
were added to the list of prohibited 
concomitant medications and procedures.  Section 7.6 Change was made to refine prohibited 
therapi[INVESTIGATOR_014]; subjects are not allowed to 
start new physical therapy programs 
for knee OA while on the study.  
The following addition was made to the 
prohibited concomitant medications and 
procedures list: “… non-surgical cosmetic 
procedures such as Botox  or other 
cosmetic  injections. ” Section 7.6 Change was made for clarification; 
other cosmetic injections are also 
allowed  during the study  
A new phone number was provided for 
the Medical Monitor.  Section 8.4.2  Change was made for administrative 
reasons  
Fax numbers were removed from Table 
1. Section 8.4.2  Change was made to avoid confusion; 
SAEs should not be reported using the 
sponsor contact [CONTACT_168997]-group analyses.  Section 10.4.8  and Section 
10.6.1 Change was made for clarification of 
subgroups  
References were added due to additions 
to the rationale section.  Section 16 Change was made for completeness; 
new references were used in the 
rationale section  
Various spelling , abbreviation, and  
grammar corrections.  Throughout  Changes were made for correctness  
and consistency  
 
 
 